Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2024 | May 13, 2024 | |
Document Information [Line Items] | ||
Document Type | 10-Q/A | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity Interactive Data Current | Yes | |
Amendment Flag | true | |
Amendment Description | References throughout this Amendment No. 1 to the Quarterly Report on Form 10-Q to “we,” “us,” the “Company” or “our company” are to Agrify Corporation.This Amendment No. 1 (“Amendment No. 1”) to the Quarterly Report on Form 10-Q/A amends the Quarterly Report on Form 10-Q of Agrify Corporation for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission (“SEC”) on May 21, 2024 (the “Original Filing”).On August 12, 2024, the Audit Committee of the Board of Directors (the “Audit Committee”) of Agrify Corporation (the “Company”), in consultation with management of the Company and the Company’s independent registered public accounting firm, GuzmanGray (“GuzmanGray”), concluded that the Company’s previously issued unaudited condensed consolidated interim financial statements as of and for the fiscal period ended March 31, 2024 included in the Company’s Quarterly Reports on Form 10-Q for such period should no longer be relied upon. Similarly, earnings releases, and investor communications describing the financial statements for the periods described above should no longer be relied upon. The Company identified an error in the accounting for a settlement agreement with a vendor which was effective in the first quarter of 2024.As such, the Company is restating in this Form 10-Q/A the unaudited consolidated interim financial statements for the three-month period ended March 31, 2024.We are filing this Amendment No. 1 to amend and restate the Original Filing with modification as necessary to reflect the restatement. The following items have been amended to reflect the restatement:Part I, Item 1, Financial InformationPart I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations | |
Document Period End Date | Mar. 31, 2024 | |
Document Fiscal Year Focus | 2024 | |
Document Fiscal Period Focus | Q1 | |
Entity Information [Line Items] | ||
Entity Registrant Name | AGRIFY CORPORATION | |
Entity Central Index Key | 0001800637 | |
Entity File Number | 001-39946 | |
Entity Tax Identification Number | 30-0943453 | |
Entity Incorporation, State or Country Code | NV | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Shell Company | false | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Contact Personnel [Line Items] | ||
Entity Address, Address Line One | 2468 Industrial Row Dr. | |
Entity Address, City or Town | Troy | |
Entity Address, State or Province | MI | |
Entity Address, Postal Zip Code | 48084 | |
Entity Phone Fax Numbers [Line Items] | ||
City Area Code | (855) | |
Local Phone Number | 420-0020 | |
Entity Listings [Line Items] | ||
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | AGFY | |
Security Exchange Name | NASDAQ | |
Entity Common Stock, Shares Outstanding | 14,229,386 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 | |
Current assets: | |||
Cash and cash equivalents | $ 95 | $ 430 | |
Marketable securities | 4 | 4 | |
Accounts receivable, net of allowance for credit losses of $2,512 and $1,887 at March 31, 2024 and December 31, 2023, respectively | 211 | 1,149 | |
Inventory, net of reserves of $17,184 and $17,599 at March 31, 2024 and December 31, 2023, respectively | 18,648 | 19,094 | |
Loan receivable, current | 692 | ||
Prepaid expenses and other current assets | 1,028 | 3,332 | |
Total current assets | 20,678 | 24,009 | |
Loan receivable, net of allowance for credit losses of $18,885 and $19,215 at March 31, 2024 and December 31, 2023, respectively, net of current | 10,891 | 11,583 | |
Property and equipment, net | 7,328 | 7,734 | |
Operating lease right-of-use assets | 1,651 | 1,803 | |
Other non-current assets | 99 | 141 | |
Total assets | 40,647 | 45,270 | |
Current liabilities: | |||
Accounts payable | 12,778 | 20,766 | |
Accrued expenses and other current liabilities | 7,843 | 10,655 | |
Operating lease liabilities, current | 615 | 599 | |
Long-term debt, current | 696 | 766 | |
Contract liabilities | 3,784 | 4,019 | |
Total current liabilities | 26,716 | 41,249 | |
Warrant liabilities | 417 | 1,290 | |
Operating lease liabilities, net of current | 1,235 | 1,394 | |
Long-term debt, net of current | 47 | 16,047 | |
Total liabilities | 46,098 | 59,980 | |
Commitments and contingencies (Note 14) | |||
Stockholders’ deficit: | |||
Common Stock, $0.001 par value per share, 35,000,000 and 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively, 13,275,702 and 1,702,243 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively (1) | [1] | 13 | 2 |
Preferred stock value | |||
Additional paid-in capital | 255,867 | 250,855 | |
Accumulated deficit | (261,561) | (265,797) | |
Total stockholders’ deficit attributable to Agrify | (5,681) | (14,940) | |
Non-controlling interests | 230 | 230 | |
Total liabilities and stockholders’ deficit | 40,647 | 45,270 | |
Related Party | |||
Current liabilities: | |||
Related party debt, current | 1,000 | 4,444 | |
Related party debt, net of current | 17,683 | ||
Preferred A Stock | |||
Stockholders’ deficit: | |||
Preferred stock value | |||
[1]Periods presented have been adjusted to reflect the 1-for-20 reverse stock split on July 5, 2023. Additional information regarding the reverse stock splits may be found in Note 1 – Overview, Basis of Presentation, and Significant Accounting Policies, included in the notes to the consolidated financial statements |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 | |
Net of allowance for credit losses (in Dollars) | $ 2,512 | $ 1,887 | |
Inventory, net of reserves (in Dollars) | 17,184 | 17,599 | |
Net of allowance for credit losses (in Dollars) | $ 18,885 | $ 19,215 | |
Common stock, par value (in Dollars per share) | [1] | $ 0.001 | $ 0.001 |
Common stock, shares authorized | [1] | 35,000,000 | 10,000,000 |
Common stock, shares issued | [1] | 13,275,702 | 1,702,243 |
Common stock, shares outstanding | [1] | 13,275,702 | 1,702,243 |
Preferred stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 | |
Preferred stock, shares authorized | 2,895,000 | 2,895,000 | |
Preferred stock, shares issued | |||
Preferred stock, shares outstanding | |||
Preferred A Stock | |||
Preferred stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 | |
Preferred stock, shares authorized | 105,000 | 105,000 | |
Preferred stock, shares issued | |||
Preferred stock, shares outstanding | |||
[1]Periods presented have been adjusted to reflect the 1-for-20 reverse stock split on July 5, 2023. Additional information regarding the reverse stock splits may be found in Note 1 – Overview, Basis of Presentation, and Significant Accounting Policies, included in the notes to the consolidated financial statements |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | ||
Income Statement [Abstract] | |||
Revenue (including $0 and $46 from related parties, respectively) | $ 2,598 | $ 5,804 | |
Cost of goods sold | 2,433 | 4,816 | |
Gross profit | 165 | 988 | |
General and administrative | 4,094 | 6,931 | |
Selling and marketing | 462 | 1,590 | |
Research and development | 275 | 735 | |
Gain on settlement of contingent liabilities | (5,935) | ||
Change in contingent consideration | (2,180) | (684) | |
Total operating expenses | (3,284) | 8,572 | |
Operating income (loss) | 3,449 | (7,584) | |
Interest expense, net | (100) | (799) | |
Change in fair value of warrant liabilities | 873 | 2,672 | |
Loss on extinguishment of long-term debt, net | (4,620) | ||
Other income, net | 14 | 4 | |
Total other income (expense), net | 787 | (2,743) | |
Net income (loss) before income taxes | 4,236 | (10,327) | |
Income tax benefit (expense) | |||
Net income (loss) | 4,236 | (10,327) | |
Net income (loss) attributable to Agrify Corporation | $ 4,236 | $ (10,327) | |
Net income (loss) per share attributable to Common Stockholders – basic (in Dollars per share) | [1] | $ 0.48 | $ (9.63) |
Net income (loss) per share attributable to Common Stockholders – diluted (in Dollars per share) | [1] | $ 0.23 | $ (9.63) |
Weighted average common shares outstanding - basic (in Shares) | 8,894,229 | 1,072,292 | |
Weighted average common shares outstanding - diluted (in Shares) | 19,960,605 | 1,072,292 | |
[1]Periods presented have been adjusted to reflect the 1-for-20 reverse stock split on July 5, 2023. Additional information regarding reverse stock splits may be found in Note 1 – Overview, Basis of Presentation, and Significant Accounting Policies, included elsewhere in the notes to the consolidated financial statements. |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Related Party | ||
Revenue from related parties | $ 0 | $ 46 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) - USD ($) $ in Thousands | Common Stock | Preferred Stock | Preferred A Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Equity (Deficit) attributable to Agrify | Non- Controlling Interests | Total |
Balance at Dec. 31, 2022 | $ 1 | $ 237,875 | $ (247,148) | $ (9,272) | $ 231 | $ (9,041) | ||
Balance (in Shares) at Dec. 31, 2022 | 1,038,298 | |||||||
Stock-based compensation | 859 | 859 | 859 | |||||
Contribution from troubled debt restructuring with related party | ||||||||
Issuance of Common Stock through an “at the market” offering, net of fees | 1,545 | 1,545 | 1,545 | |||||
Issuance of Common Stock through an “at the market” offering, net of fees (in Shares) | 323,082 | |||||||
Issuance of Common Stock to Pure Pressure | ||||||||
Issuance of Common Stock to Pure Pressure (in Shares) | 366 | |||||||
Vesting of restricted stock units | ||||||||
Vesting of restricted stock units (in Shares) | 17 | |||||||
Proceeds from Employee Stock Purchase Plan Shares | 25 | 25 | 25 | |||||
Proceeds from Employee Stock Purchase Plan Shares (in Shares) | 2,500 | |||||||
Net income (loss) | (10,327) | (10,327) | (10,327) | |||||
Balance at Mar. 31, 2023 | $ 1 | 240,304 | (257,475) | (17,170) | 231 | (16,939) | ||
Balance (in Shares) at Mar. 31, 2023 | 1,364,263 | |||||||
Balance at Dec. 31, 2023 | $ 2 | 250,855 | (265,797) | (14,940) | 230 | (14,710) | ||
Balance (in Shares) at Dec. 31, 2023 | 1,701,243 | |||||||
Stock-based compensation | 490 | 490 | 490 | |||||
Issuance of Common Stock and prefunded warrants through public offering | $ 3 | 2,120 | 2,123 | 2,123 | ||||
Issuance of Common Stock and prefunded warrants through public offering (in Shares) | 2,760,000 | |||||||
Issuance of held-back shares to Lab Society | ||||||||
Issuance of held-back shares to Lab Society (in Shares) | 588 | |||||||
Cashless exercise of High Trail Warrants | $ 3 | (3) | ||||||
Cashless exercise of High Trail Warrants (in Shares) | 3,132,217 | |||||||
Exercise of Prefunded Warrants issued through public offering | $ 3 | 3 | 3 | |||||
Exercise of Prefunded Warrants issued through public offering (in Shares) | 3,010,000 | |||||||
Conversion of Convertible Note | $ 2 | 1,729 | 1,731 | $ 1,731 | ||||
Conversion of Convertible Note (in Shares) | 2,671,633 | 2,671,633 | ||||||
Contribution from troubled debt restructuring with related party | 676 | 676 | $ 676 | |||||
Stock split share adjustment | ||||||||
Stock split share adjustment (in Shares) | 21 | |||||||
Net income (loss) | 4,236 | 4,236 | 4,236 | |||||
Balance at Mar. 31, 2024 | $ 13 | $ 255,867 | $ (261,561) | $ (5,681) | $ 230 | $ (5,451) | ||
Balance (in Shares) at Mar. 31, 2024 | 13,275,702 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Cash flows from operating activities: | ||
Net loss attributable to Agrify Corporation | $ 4,236 | $ (10,327) |
Adjustments to reconcile net income (loss) attributable to Agrify Corporation to net cash used in operating activities: | ||
Depreciation and amortization | 406 | 445 |
Amortization of debt (premium) discount | 147 | |
Amortization of issuance costs | 24 | |
Amortization of right of use assets | 152 | (133) |
Stock based compensation expense | 490 | 859 |
Change in fair value of warrant liabilities | (873) | (2,672) |
Loss on extinguishment of long-term debt, net | 4,620 | |
Provision for credit losses | 642 | |
Recovery of provision for credit losses | (330) | |
Change in inventory reserves | (415) | |
Loss on disposal of property and equipment | 2 | |
Gain on revaluation of contingent liability | (5,935) | |
Change in accrued acquisition liabilities due to issuance of held-back shares | (2,180) | |
Changes in operating assets and liabilities, net of acquisitions: | ||
Accounts receivable | 296 | (127) |
Inventory | 861 | 1,401 |
Prepaid expenses and other current assets | 2,321 | (31) |
Other non-current assets | 42 | 173 |
Accounts payable | (2,056) | 585 |
Accrued expenses and other current liabilities | (268) | (3,744) |
Operating lease liabilities | (143) | 184 |
Contract liabilities | (235) | (873) |
Net cash and cash equivalents used in operating activities | (2,987) | (9,469) |
Cash flows from investing activities: | ||
Purchases of property and equipment | (2) | (59) |
Proceeds from sale of marketable securities | 10,446 | |
Proceeds from repayment of loan receivable | 330 | |
Issuance of loans receivable | (592) | |
Net cash and cash equivalents provided by investing activities | 328 | 9,795 |
Cash flows from financing activities: | ||
Proceeds from Issuance of Common Stock through an “S-1 and Prefunded Warrants” offering | 2,123 | |
Proceeds from issuance of Common Stock through an “at the market” offering, net of fees | 1,478 | |
Proceeds from Employee Stock Purchase Plan Shares | 25 | |
Proceeds from exercise of S-1 Prefunded Warrants | 3 | |
Proceeds from issuance of related party notes | 355 | |
Repayments of notes payable, other | (71) | |
Repayment of debt in private placement | (10,307) | |
Payments on other financing loans | (1) | |
Payments on insurance financing loans | (157) | (396) |
Payments of financing leases | (35) | |
Net cash and cash equivalents provided by (used in) financing activities | 2,324 | (9,307) |
Net decrease in cash and cash equivalents | (335) | (8,981) |
Cash and cash equivalents at the beginning of period | 430 | 10,457 |
Cash and cash equivalents at the end of period | 95 | 1,476 |
Supplemental disclosures | ||
Cash paid for interest | 47 | |
Supplemental disclosures of non-cash flow information | ||
Cashless exercise of High-Trail warrants | 3 | |
Financing of prepaid insurance | 17 | 1,820 |
Trade payables refinanced into consolidated notes payable | ||
Accrued interest consolidated into related party debt | 364 | |
Contribution from troubled debt restructuring with related party | 676 | |
Consolidation of related party debt principal | 3,799 | |
Conversion of convertible notes | $ 1,731 |
Overview, Basis of Presentation
Overview, Basis of Presentation and Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2024 | |
Overview, Basis of Presentation and Significant Accounting Policies [Abstract] | |
Overview, Basis of Presentation and Significant Accounting Policies | Note 1 — Overview, Basis of Presentation and Significant Accounting Policies Description of Business Agrify Corporation (“Agrify” or the “Company”) is a provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. The Company’s proprietary micro-environment-controlled Agrify Vertical Farming Units (or “VFUs”) enable cultivators to produce the highest quality products with what we believe to be unmatched consistency, yield, and return investment at scale. The Company’s comprehensive extraction product line, which includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates. The Company was formed in the State of Nevada on June 6, 2016 as Agrinamics, Inc., and subsequently changed its name to Agrify Corporation. The Company is sometimes referred to herein by the words “we,” “us,” “our,” and similar terminology. The Company has nine wholly-owned subsidiaries, which are collectively referred to as the “Subsidiaries” and the Company also has ownership interests in certain companies. Nasdaq Deficiency Notice The Nasdaq Notice had no immediate effect on the listing of the Company’s Common Stock on The Nasdaq Stock Market LLC. On October 17, 2023, the Company received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of Nasdaq notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Listing Rule as a result of its failure to file the First Quarter Form 10-Q, the Second Quarter Form 10-Q and the Form 10-K (collectively, the “Delinquent Reports”) in a timely manner. On November 16, 2023, the Company received a notice from Nasdaq that the Company remains noncompliant with the Listing Rule as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 with the SEC by the required filing date. On December 1, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company reported stockholders’ deficit of $(17.17) million in its Form 10-Q for the quarter ended March 31, 2023, the Company was no longer in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Primary Equity Listing Rule”), which requires that listed companies maintain a minimum of $2.5 million in stockholders’ equity. In response, the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”), which stayed any further action by the Listing Qualifications Staff. The hearing was held on January 11, 2024. The Company arrived at the hearing having previously cured any additional grounds for delisting as a result of delinquent periodic filings during 2023 that were filed prior to the hearing. On January 30, 2024, the Company received formal notice that the Panel had granted the Company’s request for an exception through April 15, 2024 to evidence compliance with the Listing Rule, which was subsequently extended to May 15, 2024. Accordingly, there can be no assurance that the Company will be able to regain compliance with the Nasdaq listing rules or maintain its listing on the Nasdaq Capital Market. If the Company’s common stock is delisted, it could be more difficult to buy or sell the Company’s common stock or to obtain accurate quotations, and the price of the Company’s common stock could suffer a material decline. Delisting could also impair the Company’s ability to raise capital. On March 5, 2024, the Company received a deficiency letter from the Staff of Nasdaq notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq Stock Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. The compliance period for the Company will expire on September 3, 2024. Restatement of Previously Issued Quarterly Condensed Consolidated Financial Statements for the Three Months Ended March 31, 2024 As further described below, our unaudited condensed consolidated financial statements covering the quarterly reporting period ended March 31, 2024 have been revised to reflect the correction of errors. Restatement Background The need for the restatement arose out of the results of certain reassessment by the Company of the accounting for the settlement agreement entered into by the Company with Mack Molding Co which became effective in the first quarter of 2024 (See Note 14 - Commitments and Contingencies). Management determined that the gain from the derecognized contingent liability should be recognized fully in Q1, rather than over time as previously reported. Consequently, the Company concluded that the accounting treatment applied in the first quarter of 2024 was not appropriate. Therefore, the Company misstated inventory, accounts payable, notes payable, accumulated deficit and total stockholders’ equity (deficit), on the face of the unaudited condensed consolidated balance sheet as of March 31, 2024, and cost of goods sold, general and administrative expenses, gain on settlement of contingent liabilities, and interest income (expense), net, on the unaudited condensed consolidated statement of operations, for the three months ended March 31, 2024. The Company principally attributes the errors to a material weakness in internal controls over financial reporting, as disclosed in Item II, Part 9A of this Annual Report on Form 10-K. The Company has commenced procedures to remediate the material weaknesses. However, these material weaknesses will not be considered remediated until the applicable remedial actions have been fully implemented and the Company has concluded that these controls are operating effectively for a sufficient period of time. Restatement Adjustments The following tables summarizes the effect of the errors on the Company’s unaudited condensed consolidated balance sheet as of March 31, 2024 and unaudited condensed consolidated statement of operations and unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2024: March 31, Adjustment March 31, Inventory $ 18,862 $ (214 ) $ 18,648 Accounts payable 12,428 350 12,778 Notes payable, current $ 1,374 $ (1,374 ) $ — Notes payable, net of current 3,464 (3,464 ) — Accumulated deficit (265,835 ) 4,274 (261,561 ) Total stockholders’ equity (deficit) (9,725 ) 4,274 (5,451 ) Three Adjustment Three Cost of goods sold $ 1,869 $ 564 $ 2,433 Gross profit 729 (564 ) 165 General and administrative 2,952 1,142 4,094 Gain on settlement of contingent liabilities — (5,935 ) (5,935 ) Operating (loss) income (780 ) 4,229 3,449 Interest income (expense), net (145 ) 45 (100 ) Net (loss) income (38 ) 4,274 4,236 Basic $ 0.00 $ 0.48 $ 0.48 Diluted $ 0.00 $ 0.23 $ 0.23 While the adjustments changed net loss, gain on supply agreement, gain on revaluation of contingent liability, gain on settlement of contingent liabilities, inventory, and accounts payable line items in the unaudited condensed consolidated cash flow statement, they did not have an impact on total net cash used in operating activities, net cash used in investing activities, or net cash provided by financing activities. Three Adjustment Three Cash flows from operating activities Net loss $ (38 ) $ 4,274 $ 4,236 Adjustments to reconcile net loss to net cash used in operating activities: Gain on supply agreement (1,142 ) 1,142 — Gain on revaluation of contingent liability (564 ) 564 — Gain on settlement of contingent liabilities — (5,935 ) (5,935 ) Changes in operating assets and liabilities Inventory 1,211 (350 ) 861 Accounts payable (2,361 ) 305 (2,056 ) Net cash used in operating activities $ (2,987 ) $ — $ (2,987 ) The related notes to the unaudited condensed consolidated financial statements have also been restated to reflect the error corrections described above. Basis of Presentation and Principles of Consolidation These interim unaudited condensed consolidated financial statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring accruals) and disclosures necessary for a fair presentation of these interim unaudited condensed consolidated financial statements have been included. The results reported in the unaudited condensed consolidated financial statements for any interim periods are not necessarily indicative of the results that may be reported for the entire year. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and do not include all information and footnotes necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on April 15, 2024. Accounting for Wholly-Owned Subsidiaries The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of Agrify Corporation and its wholly-owned subsidiaries, as described above, in accordance with the provisions required by the Consolidation Topic 810 of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The Company includes results of operations of acquired companies from the date of acquisition. All significant intercompany transactions and balances are eliminated. Accounting for Less Than Wholly-Owned Subsidiaries For the Company’s less than wholly-owned subsidiaries, which include, Agrify-Valiant LLC (“Agrify-Valiant”), and Agrify Brands, LLC (“Agrify Brands”), the Company first analyzes whether these entities are a variable interest entity (a “VIE”) in accordance with ASC Topic 810, Consolidation Based on the Company’s analysis of these entities, the Company has determined that Agrify-Valiant and Agrify Brands are each a VIE, and that the Company is the primary beneficiary. While the Company owns 60% of Agrify-Valiant’s equity interests and 75% of Agrify Brand’s equity interests, the remaining equity interests in Agrify-Valiant and Agrify Brands are owned by unrelated third parties, and the agreement with these third parties provides the Company with greater voting rights. Accordingly, the Company consolidates its interest in the financial statements of Agrify-Valiant and Agrify Brands under the VIE rules and reflects the third parties’ interests in the consolidated financial statements as a non-controlling interest. The Company records this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. These non-controlling interests are not redeemable by the equity holders and are presented as part of permanent equity. Income and losses are allocated to the non-controlling interest holders based on its economic ownership percentage. Going Concern In accordance with the FASB Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements - Going Concern The Company has incurred operating losses since its inception and has negative cash flows from operations and a working capital deficit. The Company also has an accumulated deficit of $261.6 million as of March 31, 2024. The Company’s primary sources of liquidity are its cash and cash equivalents and marketable securities, with additional liquidity accessible, subject to market conditions and other factors, including limitations that may apply to the Company under applicable SEC regulations, from the capital market. As of March 31, 2024, the Company had $0.1 million of cash, cash equivalents, and marketable securities. The Company had no restricted cash as of March 31, 2024. Current liabilities were $26.7 million as of March 31, 2024. These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company believes these conditions raise substantial doubt about its ability to continue as a going concern within the next twelve-months from the date these unaudited condensed consolidated financial statements are available to be issued. The Company’s continuation as a going concern is dependent upon its ability to obtain the necessary debt or equity financing to continue operations until the Company begins generating sufficient cash flows from operations to meet its obligations. If the Company is unable raise additional funds, it may be forced to cease operations. On February 28, 2024, the company raised net proceeds of $2.2 million via the issuance of common stock and prefunded warrants in a public offering through Alexander Capital and is recorded within common stock and additional paid-in capital on the Company’s unaudited condensed consolidated balance sheet. The Company intends to raise additional capital later this year to support its 2024 and 2025 funding needs. The Company also continues to make additional adjustments in headcount, salary, travel, sales and marketing spending, but there is no guarantee that these ongoing cost-cutting efforts or capital raises will be sufficient to maintain operations. There is no assurance that the Company will ever be profitable. The unaudited condensed consolidated financial statements do not include any adjustments to reflect the potential future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates include assumptions about collection of accounts and loans receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets, the valuation of inventory, and useful life of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific information, other relevant factors that it believes to be reasonable under the circumstances, and management’s judgement. On an ongoing basis, the Company evaluates its estimates when there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual financial results could differ from those estimates. The Company regularly evaluates its assets, including asset groups or reporting units, for impairment in accordance with U.S. GAAP. The Company is aware of the impact that prolonged net losses can have on the fair value of underlying assets and the overall company. The Company is committed to ensuring that the carrying amounts of its assets are appropriately assessed and adjusted for any impairment, reflecting a true and fair view of its financial position. Accounts Receivable, Net and Loans Receivable, Net Accounts receivable, net, primarily consists of amounts for goods and services that are billed and currently due from customers. The composition of loan receivable, net is detailed in Note 5 - Loans Receivable. In accordance with ASC 310-10, accounts receivable and loan receivable balances are presented net of an allowance for credit losses, which are an estimate of billed or borrowed amounts that may not be collectible. In determining the amount of the allowance at each reporting date, management makes judgments about general economic conditions, historical write-off experience, and any specific risks identified in customer or borrower collection matters, including the aging of unpaid accounts receivable and changes in customer or borrower financial conditions. Accounts and loans receivable balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for credit losses are recorded as general and administrative expenses in the consolidated statements of operations. Concentration of Credit Risk and Significant Customer Financial instruments that potentially subject the Company to a concentration of credit risk primarily consist of cash, cash equivalents, marketable securities, accounts receivable, and loans receivable. Cash equivalents primarily consist of money market funds with original maturities of three months or less, which are invested primarily with U.S. financial institutions. Cash deposits with financial institutions generally exceed federally insured limits. Management believes minimal credit risk exists with respect to these financial institutions and the Company has not experienced any losses on such amounts. During the year three -month period ended March 31, 2024, the Company has one customer that comprised approximately 1% of its revenue and two customers that comprised approximately 47% of its accounts receivable balance. During the year three -month period ended March 31, 2023, the Company has one customer that comprised approximately 11% of its revenue and two customers that comprised approximately 84% of it accounts receivable balance. Inventories The Company values all its inventories, which consist primarily of significant raw material hardware components, at the lower of cost or net realizable value, with cost principally determined by the weighted-average cost method on a first-in, first-out basis. Write-offs of potentially slow-moving or damaged inventory are recorded through specific identification of obsolete or damaged material. The Company takes a physical inventory count at least once annually at all inventory locations. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expenses are recognized using the straight-line method over the estimated useful life of each asset, as follows: Estimated Useful Life (Years) Computer and office equipment 2 to 3 Furniture and fixtures 2 Software 3 Vehicles 5 Research and development of laboratory equipment 5 Machinery and equipment 3 to 5 Leased equipment 5 to 13 Trade show assets 3 to 5 Leasehold improvements Lower of estimated useful life or remaining lease term The estimated useful lives of the Company’s property and equipment are periodically assessed to determine if changes are appropriate. The Company charges maintenance and repairs to expense as incurred. When the Company retires or disposes of assets, the carrying cost of these assets and related accumulated depreciation or amortization are eliminated from the condensed consolidated balance sheets and any resulting gain or loss is included in the condensed consolidated statements of operations in the period of retirement or disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. During construction, costs are accumulated in a construction-in-progress account, with no depreciation. Upon completion, costs are transferred to the appropriate asset account, and depreciation begins when the asset is placed into service. Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all its financial instruments, including issued private placement stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480, Distinguishing Liabilities from Equity For issued or modified warrants that meet all of the criteria for equity classification, they are recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that are precluded from equity classification, they are recorded as a liability at their initial fair value on the date of issuance and subject to remeasurement on each balance sheet date with changes in the estimated fair value of the warrants to be recognized as an unrealized gain or loss in the unaudited condensed consolidated statements of operations. Fair Value of Financial Instruments The Company’s financial instruments consist of cash, marketable securities, accounts receivable, accounts payable, accrued expenses, warrant liabilities, and loans receivable. Refer to Note 4 - Fair Value Measures, included elsewhere in the notes to the unaudited condensed consolidated financial statements for details of the Company’s financial instruments. Revenue Recognition Overview The Company generates revenue from the following sources: (1) equipment sales, (2) providing services and (3) construction contracts. In accordance with ASC 606 Revenue Recognition ● identify the customer contract; ● identify performance obligations that are distinct; ● determine the transaction price; ● allocate the transaction price to the distinct performance obligations; and ● recognize revenue as the performance obligations are satisfied. Identify the customer contract A customer contract is generally identified when there is approval and commitment from both the Company and its customer, the rights have been identified, payment terms are identified, the contract has commercial substance and collectability is probable. Specifically, the Company obtains written/electronic signatures on contracts and purchase orders, if said purchase orders are issued in the normal course of business by the customer. Identify performance obligations that are distinct A performance obligation is a promise by the Company to provide a distinct good or service or a series of distinct goods or services. A good or service that is promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer, and a company’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determine the transaction price The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer, excluding sales taxes that are collected on behalf of government agencies. Allocate the transaction price to distinct performance obligations The transaction price is allocated to each performance obligation based on the relative standalone selling prices (“SSP”) of the goods or services being provided to the customer. The Company’s contracts typically contain multiple performance obligations, for which the Company accounts for individual performance obligations separately, if they are distinct. The standalone selling price reflects the price the Company would charge for a specific piece of equipment or service if it was sold separately in similar circumstances and to similar customers. Recognize revenue as the performance obligations are satisfied Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer. Significant Judgments The Company enters into contracts that may include various combinations of equipment, services and construction, which are generally capable of being distinct and accounted for as separate performance obligations. Contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Once the Company determines the performance obligations, it determines the transaction price, which includes estimating the amount of variable consideration to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on the SSP. The corresponding revenue is recognized as the related performance obligations are satisfied. Judgment is required to determine the SSP for each distinct performance obligation. The Company determines SSP based on the price at which the performance obligation is sold separately and the methods of estimating SSP under the guidance of ASC 606-10-32-33. If the SSP is not observable through past transactions, the Company estimates the SSP, taking into account available information such as market conditions, expected margins, and internally approved pricing guidelines related to the performance obligations. The Company licenses its software as a service (“SaaS”) type subscription license, whereby the customer only has a right to access the software over a specified time period. The full value of the contract is recognized ratably over the contractual term of the SaaS subscription, adjusted monthly if tiered pricing is relevant. The Company typically satisfies its performance obligations for equipment sales when equipment is made available for shipment to the customer; for services sales as services are rendered to the customer and for construction contracts both as services are rendered and when the contract is completed. The Company utilizes the cost-plus margin method to determine the SSP for equipment and build-out services. This method is based on the cost of the services from third parties, plus a reasonable markup that the Company believes is reflective of a market-based reseller margin. The Company determines the SSP for services in time and materials contracts by observable prices in standalone services arrangements. The Company estimates variable consideration in the form of royalties, revenue share, monthly fees, and service credits at contract inception and updated at the end of each reporting period if additional information becomes available. Variable consideration is typically not subject to constraint. Changes to variable consideration were not material for the periods presented. If a contract has payment terms that differ from the timing of revenue recognition, the Company will assess whether the transaction price for those contracts include a significant financing component. The Company has elected the practical expedient that permits an entity to not adjust for the effects of a significant financing component if the Company expects that at the contract inception, the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service, will be one year or less. For those contracts in which the period exceeds the one-year threshold, this assessment, as well as the quantitative estimate of the financing component and its relative significance, requires judgment. Accordingly, the Company imputes interest on such contracts at an agreed-upon interest rate and will present the financing components separately as financial income. As of March 31, 2024 and March 31, 2023, the Company did not have any such financial income. Payment terms with customers typically require payment 30 days from the invoice date. The Company’s agreements with its customers do not provide for any refunds for services or products and therefore no specific reserve for such is maintained. In the infrequent instances where customers raise concern over delivered products or services, the Company has endeavored to remedy the concern and all costs related to such matters have been insignificant in all periods presented. The Company has elected to treat shipping and handling activities after the customer obtains control of the goods as a fulfillment cost and not as a promised good or service. Accordingly, the Company will accrue all fulfillment costs related to the shipping and handling of consumer goods at the time of shipment. The Company has payment terms with its customers of one year or less and has elected the practical expedient applicable to such contracts not to consider the time value of money. Sales, value add, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company receives payment from customers based on specified terms that are generally less than 30 days from the satisfaction of performance obligations. There are no contract assets related to performance under the contract. The difference in the opening and closing balances of the Company’s contract liabilities primarily results from the timing difference between the Company’s performance and the customer’s payment. The Company fulfills obligations under a contract with a customer by transferring products and services in exchange for consideration from the customer. Accounts receivable are recorded when the customer has been billed or the right to consideration is unconditional. The Company recognizes a contract liability when consideration has been received or an amount of consideration is due from the customer, and the Company has a future obligation to transfer certain proprietary products. In accordance with ASC 606-10-50-13, the Company is required to include disclosure on its remaining performance obligations as of the end of the current reporting period. Due to the nature of the Company’s contracts, these reporting requirements are not applicable. The majority of the Company’s remaining contracts meet certain exemptions as defined in ASC 606-10-50-14 through 606-10-50-14A, including (i) performance obligation is part of a contract that has an original expected duration of one year or less and (ii) the right to invoice practical expedient. The Company generally provides a one-year warranty on its products for materials and workmanship but may provide multiple year warranties as negotiated, and generally transfers to its customers the warranties it receives from its vendors, if any, which generally cover this one-year period. In accordance with ASC 450-20-25, the Company accrues for product warranties when the loss is probable and can be reasonably estimated. The Company maintained a reserve for warranty returns of $0.4 million and $0.4 million as of March 31, 2024 and December 31, 2023, respectively. The Company’s reserve for warranty returns is included in accrued expenses and other current liabilities in its unaudited condensed consolidated balance sheets. Additional information regarding the Company’s warranty reserve may be found in Note 3 – Supplemental Consolidated Balance Sheet Information, included elsewhere in the notes to the unaudited condensed consolidated financial statements. Research and Development Costs The Company expenses research and development costs as incurred. Research and development expenses include payroll, employee benefits and other expenses associated with product development. The Company incurs research and development costs associated with the development and enhancement of both hardware and software products associated with its cultivation and extraction equipment, as well as its SaaS-based software offering, Agrify Insights™ cultivation software (“Agrify Insights™”). Net Loss Per Share The Company presents basic and diluted net (loss) income per share attributable to common stockholders in conformity with the one-class method. The Company computes basic (loss) income per share by dividing net (loss) income available to common stockholders by the weighted-average number of common st |
Revenue and Contract Liabilitie
Revenue and Contract Liabilities | 3 Months Ended |
Mar. 31, 2024 | |
Revenue and Contract Liabilities [Abstract] | |
Revenue and Contract Liabilities | Note 2 — Revenue and Contract Liabilities Revenue The Company sells its equipment and services to customers under a combination of a contract and purchase order. Equipment revenue includes sales from proprietary products designed and engineered by the Company such a VFUs, container farms, integrated grow racks, and LED grow lights, and non-proprietary products designed, engineered, and manufactured by third parties such as air cleaning systems and pesticide-free surface protection. Construction contracts normally provide for payment upon completion of specified work or units of work as identified in the contract. Although there is considerable variation in the terms of these contracts, they are primarily structured as time-and-materials contracts. The Company enters into time-and-materials contracts under which the Company is paid for labor and equipment at negotiated hourly billing rates and other expenses, including materials, as incurred at rates agreed to in the contract. The Company uses three main sub-contractors to execute the construction contracts. The following table provides the Company’s revenue disaggregated by the timing of revenue recognition: Three months ended (In thousands) 2024 2023 Transferred at a point in time $ 2,465 $ 4,920 Transferred over time 133 884 Total revenue $ 2,598 $ 5,804 In accordance with ASC 606-10-50-13, the Company is required to include disclosure on its remaining performance obligations as of the end of the current reporting period. Due to the nature of the Company’s contracts, these reporting requirements are not applicable because the majority of the Company’s remaining contracts meet certain exemptions as defined in ASC 606-10-50-14 through 606-10-50-14A, including (i) performance obligation is part of a contract that has an original expected duration of one year or less and (ii) the right to invoice practical expedient. Contract Liabilities Changes in the Company’s current contract liabilities balance for the three months ended March 31, 2024 and the year ended December 31, 2023 were as follows: (In thousands) Three Year Contract liabilities – beginning of period $ 4,019 $ 4,112 Additions 1,160 4,905 Recognized (1,395 ) (4,998 ) Contract liabilities – end of period $ 3,784 $ 4,019 Contract liabilities balances primarily consist of customer deposits on the Company’s cultivation and extraction solutions equipment. As of March 31, 2024 and December 31, 2023, all of the Company’s contract liabilities balances were reported as current liabilities in the accompanying unaudited condensed consolidated balance sheets. |
Supplemental Condensed Consolid
Supplemental Condensed Consolidated Balance Sheet Information | 3 Months Ended |
Mar. 31, 2024 | |
Supplemental Consolidated Balance Sheet Information [Abstract] | |
Supplemental Condensed Consolidated Balance Sheet Information | Note 3 — Supplemental Condensed Consolidated Balance Sheet Information Accounts Receivable, net Accounts receivable consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Accounts receivable, gross $ 2,723 $ 3,036 Less allowance for credit losses (2,512 ) (1,887 ) Accounts receivable, net $ 211 $ 1,149 The changes in the allowance for credit losses accounts consisted of the following: (In thousands) Three Year Allowance for credit losses - beginning of period $ 1,887 $ 4,605 (Recovery of) allowance for credit losses 642 (1,426 ) Accounts receivable written-off (17 ) (1,292 ) Allowance for credit losses - end of period $ 2,512 $ 1,887 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Other receivables, other $ 536 $ 659 Prepaid insurance 352 454 Prepaid expenses, other 93 82 Prepaid software 31 70 Prepaid materials 16 13 Prepaid settlement asset — 2,054 Total prepaid expenses and other current assets $ 1,028 $ 3,332 The Company recorded in the fourth quarter of the year ended December 31, 2023 a prepaid settlement asset in connection with the Modification and Settlement Agreement entered into with Mack Molding Co. as described in detail within Note 14 — Commitments and Contingencies. This amount represents the value of warrants to be issued to Mack Molding Co. upon satisfaction of the terms of the settlement agreement and one $500 thousand prepayment to Mack Molding Co. During the quarter ended March 31, 2024, the conditions of the agreement were met and the prepaid settlement asset was derecognized and recorded into gain on settlement of contingent liabilities upon the closing of the settlement. Property and Equipment, Net Property and equipment, net consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Leased equipment $ 4,465 $ 4,465 Leasehold improvements 702 702 Machinery and equipment 904 904 Software 606 606 Computer and office equipment 588 588 Research and development laboratory equipment 183 183 Furniture and fixtures 116 116 Trade show assets 78 78 Vehicles 43 43 Total property and equipment, gross 7,685 7,685 Accumulated depreciation (3,300 ) (2,894 ) Construction in progress 2,943 2,943 Total property and equipment, net $ 7,328 $ 7,734 Depreciation expense for the three months ended March 31, 2024 and 2023 was $0.4 million and $0.4 million, respectively, and included within general and administrative, selling and marketing, and research and development depending on the nature of the related property and equipment. Construction in Progress (“CIP”) includes all direct and indirect costs related to the construction, development, or acquisition of tangible property and equipment that is not yet ready for use. All costs incurred during the construction phase are accumulated in the CIP account. Costs remain in the CIP account until the asset is substantially complete and ready for its intended use. Once the asset is ready for use, the total accumulated costs are transferred from the CIP account to the appropriate property and equipment account. The asset is then depreciated over its estimated useful life from the date it is placed into service. CIP is reviewed regularly to ensure that all costs are accurate and that the project is progressing as planned. Any indication of impairment is assessed, and if the carrying amount exceeds the recoverable amount, an impairment loss is recognized. During the year ended December 31, 2023, the Company sold property and equipment in exchange for proceeds of $105,000, resulting in a gain of $144,000. During the year ended December 31, 2023, the Company retired certain fully depreciated property and equipment which had an original cost of $444,000. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Sales tax payable (1) $ 5,320 $ 5,338 Accrued construction costs 1,312 1,412 Accrued professional fees 423 457 Accrued warranty expenses 415 420 Compensation related fees 313 474 Accrued consulting fees 45 43 Accrued interest expense 12 321 Accrued inventory purchases 3 10 Accrued acquisition liabilities — 2,180 Total accrued expenses and other current liabilities $ 7,843 $ 10,655 (1) Sales tax payable primarily represents identified sales and use tax liabilities arising from our acquisition of Precision and Cascade. These amounts are included as part of our initial purchase price allocations and are the subject matter of an indemnification claim under the Precision and Cascade acquisition agreement. Accrued acquisition liabilities Resulting from the 2021 acquisitions of Precision Extraction Newco, LLC (“Precision”) and Cascade Sciences, LLC (“Cascade”) from Sinclair Scientific, LLC (“Sinclair”), the Company withheld from the transaction shares issuable to Precision and Cascade for the purpose of securing any post-closing adjustment owed to the Company and any claim for indemnification or payment of damages to which the Company may be entitled under the purchase agreement. The accrued acquisition liabilities as of December 31, 2023 represent the value of this held back Common Stock at the price per share at the time of the transaction. On June 15, 2023, the Company and its wholly-owned subsidiary, Precision, filed an Amended Verified Complaint in the Court of Chancery of the State of Delaware against Sinclair and certain individual defendants (the “Delaware Action”). The claims filed in the Delaware Action concern various breaches of the Plan of Merger and Equity Purchase Agreement dated September 29, 2021, by and between the Company, Sinclair, Mass2Media, LLC, and certain of their members (the “Merger Agreement”). In response to the Delaware Action, certain of the defendants filed counterclaims for breach of contract and declaratory judgment against the Company and Precision alleging breach of the Merger Agreement. Pursuant to a Settlement and Release Agreement, dated December 14, 2023, the Company and Sinclair dismissed all legal claims and entered into a settlement for an undisclosed amount. As a result of this settlement, the Company derecognized the accrued acquisition liability and issued the held back Common Stock in the first quarter of 2024 at Agrify’s price per share at the time of issuance. The difference between the value of the shares at issuance and the derecognized liabilities was recorded as a gain within change in contingent consideration within the Company’s condensed and consolidated statement of operations for the three months ended March 31, 2024. |
Fair Value Measures
Fair Value Measures | 3 Months Ended |
Mar. 31, 2024 | |
Fair Value Measures [Abstract] | |
Fair Value Measures | Note 4 — Fair Value Measures Fair Values of Assets and Liabilities In accordance with ASC Topic 820 “Fair Value Measurement”, the Company measures fair value at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the assumptions that market participants would use in pricing an asset or liability (the inputs) are based on a tiered fair value hierarchy consisting of three levels, as follows: Level 1: Observable inputs such as quoted prices for identical assets or liabilities in active markets. Level 2: Other inputs that are observable directly or indirectly, such as quoted prices for similar instruments in active markets or for similar markets that are not active. Level 3: Unobservable inputs for which there is little or no market data which require the Company to develop its own assumptions about how market participants would price the asset or liability. Valuation techniques for assets and liabilities include methodologies such as the market approach, the income approach or the cost approach, and may use unobservable inputs such as projections, estimates and management’s interpretation of current market data. These unobservable inputs are only utilized to the extent that observable inputs are not available or cost-effective to obtain. At March 31, 2024 and December 31, 2023, the Company’s assets and liabilities measured at fair value on a recurring basis were as follows: March 31, 2024 December 31, 2023 Fair Value Measurements Using Input Types Fair Value Measurements Using Input Types (In thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Money market funds 4 — — 4 4 — — 4 Total assets $ 4 $ — $ — $ 4 $ 4 $ — $ — $ 4 Liabilities: Warrant liabilities - January 2022 warrants $ — $ — $ — $ — $ — $ — $ 1 $ 1 Warrant liabilities - March 2022 warrants — — 1 1 — — 7 7 Warrant liabilities - August 2022 warrants — — 3 3 — — 18 18 Warrant liabilities - December 2022 warrants — — 413 413 — — 1,264 1,264 Total liabilities $ — $ — $ 417 $ 417 $ — $ — $ 1,290 $ 1,290 Fair Value of Financial Instruments The Company has certain financial instruments which consist of cash and cash equivalents, marketable securities, accounts receivable, loans receivable, accounts payable, accrued expenses, contingent consideration, operating lease liabilities, long-term debt, related party debt, and warrant liabilities. Fair value information for each of these instruments as well as other balances of the Company are as follows: ● Cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value based on the short-term nature of these instruments. ● Marketable securities classified as current held-to-maturity securities are recorded at amortized cost, which at March 31, 2024 and December 31, 2023, approximated fair value. ● Loans receivable are presented net of an allowance for estimated credit losses, which approximates fair value. ● The Company’s contingent consideration was recorded in connection with acquisitions during the three months ended March 31, 2024 and fiscal 2023 using an estimated fair value discount at the time of the transactions. As of March 31, 2024 and December 31, 2023, the carrying value of the contingent consideration approximated fair value. ● The carrying value of lease liabilities approximates fair value due to the implicit discount rates used in the determination of the lease liabilities being consistent with the Company’s incremental borrowing rates at the time of lease inception and accounting for the duration of the leases. ● Long-term debt and related party debt, including the debt that has undergone troubled debt restructuring, is carried at amortized cost, dictated by the prevailing market interest rates at the time of each transaction in accordance with ASC 470, Debt ● The Company’s warrant liabilities are marked-to-market each reporting period with the changes in fair value of warrant liabilities recorded in other income (expense), net in the accompanying unaudited condensed consolidated statements of operations until the warrants are exercised. The fair value of the warrant liabilities are estimated using a Black-Scholes option-pricing model. Marketable Securities As of March 31, 2024 and December 31, 2023, the Company held investments in money market funds. They are valued using quoted market prices in active markets and are classified under Level 1 within the fair value hierarchy. The fair value of the Company’s money market funds as of March 31, 2024 and December 31, 2023 is $4 thousand for both years, respectively. Warrant Liabilities The estimated fair value of the warrant liabilities on March 31, 2024 and 2023 is determined using Level 3 inputs. Inherent in a Black-Scholes option-pricing model are assumptions used in calculating the estimated fair values that represent the Company’s best estimate. The volatility rate is determined utilizing the Company’s own share price and the share price of competitors over time. However, inherent uncertainties are involved. If factors or assumptions change, the estimated fair values could be materially different. The following table summarizes the Company’s assumptions used in the valuations as of March 31, 2024 and December 31, 2023: January March August December January March August December March 31, 2024 December 31, 2023 Stock price $ 0.37 $ 0.37 $ 0.37 $ 0.37 $ 1.26 $ 1.26 $ 1.26 $ 1.26 Exercise price $ 1,496 $ 430 $ 246 $ 0.38 $ 1,496 $ 430 $ 246 $ 3.45 Expected term (in Years) 3.32 3.88 3.88 3.88 3.57 4.13 4.13 4.13 Volatility 136.00 % 138.00 % 138.00 % 138.00 % 138.00 % 136.00 % 136.00 % 136.00 % Discount rate - treasury yield 4.37 % 4.32 % 4.32 % 4.32 % 3.96 % 3.91 % 3.91 % 3.91 % The following table sets forth a summary of the changes in the fair value of the Level 3 warrant liabilities for the three months ended March 31, 2024 and for the year ended December 31, 2023: (In thousands) March 31, For the Warrant liabilities – beginning of period $ 1,290 $ 5,985 Change in estimated fair value (873 ) (4,695 ) Warrant liabilities –end of period $ 417 $ 1,290 |
Loans Receivable
Loans Receivable | 3 Months Ended |
Mar. 31, 2024 | |
Loans Receivable [Abstract] | |
Loans Receivable | Note 5 — Loans Receivable A portion of the capital raised from the Company’s IPO was allocated to launch the Company’s TTK Solution program. TTK Solution is the industry’s first-of-its-kind program in which the Company engages with qualified cannabis operators in the early phases of their business plans and provides critical support, typically over a 10-year period, which includes: access to capital for construction costs, the design and build-out of their cultivation and extraction facilities, state-of-the-art cultivation and extraction equipment, subscription to the Company’s Agrify Insights™, process design, training, implementation, proven grow recipes, product formulations, data analytics, and consumer branding. Bud & Mary’s Cultivation, Inc. (“Bud & Mary’s”) - Customer 139 The initial payment date on the loan receivable from Bud & Mary’s is the first business day of the first full month following the commencement of commercial products sales and the maturity date is 24 months from the initial payment date. The interest rate is 16% per annum. In Q3 2022, Agrify became aware that Bud & Mary’s was not in compliance with all debt covenants as defined in the loan agreement which resulted in Agrify issuing a loan acceleration letter to Bud & Mary’s on September 15, 2022, demanding full repayment of the construction loan under the loan agreement dated May 12, 2021. Consequently, the Company established a reserve of $14.7 million specifically related to Bud & Mary’s. As of March 31, 2024 the allowance related to Bud & Mary’s was reduced to $14.4 million, reflecting a recovery of allowance for credit losses resulting from a loan repayment of $330 thousand that was previously included in the allowance. Hannah Industries (“Hannah”) - Customer 125 As of December 31, 2022, the Company was unable to provide additional financing to Hannah Industries under the TTK Solution program to complete the build out and development of Hannah’s cultivation business. As a result, the Company concluded that the existing receivable due from Hannah was impaired as of this date. Given the uncertainty around the customer’s ability to repay the outstanding balance of the loan as well as the absence of value attributed to any collateral from Hannah, an allowance for credit losses was recognized for 50% of the total outstanding receivable balance as of December 31, 2022. The Company recognized an allowance for credit losses related to the Hannah loan receivable in the amount of $4.5 million as of December 31, 2022. In October 2023, the Company remitted an additional $250 thousand to Hannah under the TTK Solution program, on which an allowance was not recorded. Therefore the allowance on the Hannah loan remains at $4.5 million as of March 31, 2024. Once the project is completed, the customer will begin making monthly payments based on the harvest. Nevada Holistics (“Tree house”) - Customer 24096 As of March 2024, Nevada Holistics has a current balance of $692 due in relation to the TTK loan. The project went live in Q2 2023. After the 90 day period for the first harvest, the customer was given an additional 6-month grace period which ended in Q1 2024. Upon completion of this grace period, the Company began invoicing the customer each month for a portion of the outstanding loan balance. The borrower will begin making monthly payments in Q2 2024 based on what is produced through harvests. Monthly payments are calculated based off of the Production Success Fees (‘PSF”) generated from each harvest. Upon issuance of each invoice, that portion of the loan is reclassified into loan receivable, current on the unaudited condensed consolidated balance sheets. The breakdown of loans receivable by customer as of March 31, 2024 and December 31, 2023 were as follows: (In thousands) March 31, December 31, Customer 139 $ 14,361 $ 14,691 Customer 125 9,297 9,297 Customer 24096 6,810 6,810 Allowance for credit losses (18,885 ) (19,215 ) Total loan receivable, net of allowance for credit losses $ 11,583 $ 11,583 Less: current portion (692 ) — Total loan receivable, net of current $ 10,891 $ 11,583 |
Inventory
Inventory | 3 Months Ended |
Mar. 31, 2024 | |
Inventory [Abstract] | |
Inventory | Note 6 — Inventory Inventories are stated at the lower of cost or net realizable value, with cost principally determined by the weighted-average cost method on a first-in, first-out basis. Such costs include the acquisition cost for raw materials and operating supplies. The Company’s standard payment terms with suppliers may require making payments in advance of delivery of the Company’s products. The Company’s prepaid inventory is applied to the purchase of products once they are delivered. Inventory consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Raw materials $ 22,392 $ 23,449 Prepaid inventory 816 924 Finished goods 7,848 7,438 Inventory for resale 4,776 4,882 Inventory, gross 35,832 36,693 Inventory reserves (17,184 ) (17,599 ) Total inventory, net $ 18,648 $ 19,094 Inventory Reserves The Company establishes an inventory reserve for obsolete, slow moving, and defective inventory. The Company calculates inventory reserves for obsolete, slow moving, or defective items as the difference between the cost of inventory and its estimated net realizable value. The reserves are based upon management’s expected method of disposition. Changes in the Company’s inventory reserve are as follows: (In thousands) Three Year Inventory reserves – beginning of period $ 17,599 $ 32,422 (Decrease) increase in inventory reserves (415 ) (14,823 ) Inventory reserves – end of period $ 17,184 $ 17,599 |
Debt
Debt | 3 Months Ended |
Mar. 31, 2024 | |
Debt [Abstract] | |
Debt | Note 7 – Debt The Company’s debt consisted of: (In thousands) March 31, December 31, Related party debt: Consolidated CP Acquisitions Note $ 17,683 $ — CP Acquisitions Junior Secured Note — 3,799 GIC Acquisition Note 1,000 645 Total related party debt 18,683 4,444 Less: current portion (1,000 ) (4,444 ) Related party debt, net of current $ 17,683 $ — Long-term debt: Exchange Note $ — $ 6,669 Convertible Note — 7,840 PPP Loan 517 518 Other notes payable (1) 226 367 Unamortized debt premium — 1,419 Total long-term debt 743 16,813 Less: current portion (696 ) (766 ) Long-term debt, net of current $ 47 $ 16,047 (1) Other notes payable relates to a one-year insurance premium that was financed over nine-months and incurred interest expense of approximately $7 thousand for the three months ended March 31, 2024. Other notes payable also includes the Navitas Loan with a balance of $5 thousand as of March 31, 2024. Exchange Note The Exchange Note is a senior secured obligation of the Company and ranks senior to all indebtedness of the Company. The Exchange Note will mature on the three-year anniversary of its issuance (the “Maturity Date”) and contains a 9.0% annualized interest rate, with interest to be paid monthly, in cash, beginning September 1, 2022. The principal amount of the Exchange Note will be payable on the Maturity Date, provided that the Lender was entitled to a cash sweep of 20% of the proceeds received by the Company in connection with any equity financing, which will reduce the outstanding principal amount under the Exchange Note. Convertible Note On March 8, 2023, as a result of the Exchange Agreement, the Company issued a Convertible Note to Lender with a principal balance of $10 million. The Convertible Note bears a 9.0% annualized interest rate, with interest to be paid monthly, in cash, beginning April 1, 2023. The principal amount of the Convertible Note will be payable on the Maturity Date, provided that the Lender was entitled to a cash sweep of 30% of the proceeds of any at-the-market equity offering and 20% of the proceeds received by the Company in connection with any other equity financing, which would reduce the outstanding principal amount under the August 2022 Note or the Convertible Note. At any time, the Company may prepay all of the Convertible Note by redemption at a price equal to 102.5% of the then-outstanding principal amount under the Convertible Note plus accrued but unpaid interest. The Lender had the option of requiring the Company to redeem the Convertible Note (i) on August 19, 2023 or August 19, 2024 at a price equal to the then-outstanding principal amount under the Convertible Note plus accrued but unpaid interest, provided that the redemption right on August 19, 2023 will not be exercisable if the Company raises at least $8.0 million in gross proceeds from equity offerings prior to such date, or (ii) if the Company undergoes a fundamental change (as defined below) at a price equal to 102.5% of the then-outstanding principal amount under the Convertible Note plus accrued but unpaid interest. The Convertible Note imposed certain customary affirmative and negative covenants upon the Company, as well as covenants that will (i) restrict the Company and its subsidiaries from incurring any additional indebtedness or suffering any liens, subject to specified exceptions, (ii) restrict the ability of the Company and its subsidiaries from making certain investments, subject to specified exceptions, and (iii) restrict the declaration of any dividends or other distributions, subject to specified exceptions. If an event of default under the Convertible Note occurs, the Lender can elect to redeem the Convertible Note for cash equal to (A) 115% of the then-outstanding principal amount of the Convertible Note (or such lesser principal amount accelerated by the Lender), plus accrued and unpaid interest, including default interest, which accrues at a rate per annum equal to 15% from the date of a default or event of default, or, only in connection with certain events of default, (B) the greater of the amount under clause (A) or the sum of (i) 115% of the product of (a) the conversion rate in effect as of the trading day immediately preceding the date that the Lender delivers a notice of acceleration; (b) the total then outstanding principal amount under the Convertible Note (in thousands); and (c) the greater of (1) the highest daily volume weighted average price (“VWAP”) per share of Common Stock occurring during the fifteen consecutive trading days ending on, and including, the trading day immediately before the date the Lender delivers such notice and (2) the highest daily VWAP per share of Common Stock occurring during the fifteen consecutive trading days ending on, and including, the trading immediately before the date the applicable event of default occurred and (ii) the accrued and unpaid interest on the Convertible Note. Until the date the Convertible Note is fully repaid, the Lender had, subject to certain exceptions, the right to participate for up to 30% of any offering of debt, equity (other than an offering of solely Common Stock), or equity-linked securities, including without limitation any debt, preferred stock or other instrument or security, of the Company or its subsidiaries. If the Lender elected to convert the Convertible Note, the conversion price per share would be $7.64, subject to customary adjustments for certain corporate events. The conversion of the Convertible Note will be subject to certain customary conditions. The Convertible Note may not be converted into shares of Common Stock if such conversion would result in the Lender and its affiliates owning an aggregate of in excess of 4.99% of the then-outstanding shares of Common Stock, provided that upon 61 days’ notice, such ownership limitation may be adjusted by the Lender, but in any case, to no greater than 9.99%. The Company evaluated the embedded features in accordance with ASC 815-15-25 and the determined embedded features are not required to be bifurcated and separately measured at fair value. Aggregate interest expense related to the Convertible Note and Exchange Note described above was $116 thousand as of March 31, 2024. Note Conversion Pursuant to the Exchange Agreement the Company entered into with the Lender on March 8, 2023, the Lender elected, on April 26, 2023, to convert $1.6 million of the remaining outstanding principal amount on the Convertible Note for 153,617 shares of Common Stock of the Company. On May 1, 2023, the Company entered into a letter agreement with the above referenced accredited Lender (the “Letter Agreement”), pursuant to which the Company and the Lender agreed to exchange or redeem $2.0 million of the remaining outstanding principal amount under the Exchange Note for a total of 445,196 shares of Common Stock of the Company, subject to a Beneficial Ownership Limitation of 4.99% of the Company’s Common Stock. Due to the Beneficial Ownership Limitation of 4.99%, a total of 69,568 shares of Common Stock of the Company were issued to the Lender, with the remaining 375,629 shares held in abeyance until the balance (or portion thereof) may be issued in compliance with such limitations. As a result, the Company recognized a loss on the redemption of approximately $12 thousand. The total aggregated Exchange Note and Convertible Note is classified as long-term as of March 31, 2024. Convertible Note Forgiveness On November 30, 2023, the New Lender agreed to forgive $1.0 million of the principal amount outstanding on the Convertible Note (the “Principal Forgiveness”). The Principal Forgiveness was accounted for as a troubled debt restructuring under ASC 470, as 1) the Company was determined to be experiencing financial difficulties as defined by the ASC, and 2) the Principal Forgiveness was deemed a concession by the New Lender. Per ASC 470-60-35-5, a debtor in a troubled debt restructuring involving only modification of terms of a payable (i.e., not involving a transfer of assets or grant of an equity interest) shall account for the effects of the restructuring prospectively from the time of restructuring and shall not change the carrying amount of the payable at the time of the restructuring unless the carrying amount exceeds the total future cash payments specified by the new terms. As the future undiscounted cash flows were greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed. CP Acquisitions Junior Secured Note On October 27, 2023, CP Acquisitions LLC (the “New Lender” or “CP”), an entity affiliated with and controlled by the Company’s Chief Executive Officer, purchased the Exchange Note and the Convertible Note from their holder (the “Note Purchase”). In connection with the Note Purchase, the New Lender has agreed to waive any events of default under the acquired notes through December 31, 2023. As part of the same transaction, the Company issued a junior secured promissory note (the “Junior Secured Note”) to the New Lender. Pursuant to the Junior Secured Note, the New Lender will lend up to $3.0 million to the Company. The Junior Secured Note bears interest at a rate of 10% per annum, will mature in full on December 31, 2023, and may be prepaid without any fee or penalty. On December 4, 2023, the New Lender and the Company amended and restated the Junior Secured Note agreement. Pursuant to the terms of the amendment, the maximum principal amount that may be loaned by CP to the Company was increased to $4.0 million and extended the maturity date thereon to December 31, 2024. Consolidated CP Acquisitions Note On January 25, 2024, the Company and the New Lender consolidated the outstanding principal and interest due under the Junior Secured Note and the Exchange Note as well as the interest due under the Convertible Note into the Convertible Note (collectively, with the Junior Secured Note and the Exchange Note, the “Consolidated Notes”), and amended and restated the Convertible Note under a Senior Secured Amended, Restated, and Consolidated Convertible Note agreement (the “Restated Note”) having a total outstanding principal of $18,717,973 (the “New Lender Debt Consolidation”). The Restated Note bears interest at a rate of 10% per annum and will mature in full on December 31, 2025. The Company may redeem all or a portion not less than $5.0 million of principal at any time at a price equal to 102.5% of the redeemed principal amount plus accrued but unpaid interest. The Restated Note imposes certain customary affirmative and negative covenants upon the Company, as well as covenants that will (i) restrict the Company and its subsidiaries from incurring any additional indebtedness or suffering any liens, subject to specified exceptions, (ii) restrict the ability of the Company and its subsidiaries from making certain investments, subject to specified exceptions, and (iii) restrict the declaration of any dividends or other distributions, subject to specified exceptions. If an event of default under the Restricted Note occurs, then the then outstanding principal and all accrued and unpaid interest on the Restated Note will immediately become due and payable. If the New Lender elects to convert the Restated Note, the conversion price per share will be $1.46, subject to customary adjustments for certain corporate events. The conversion of the Restated Note will be subject to certain customary conditions. The Restated Note may not be converted into shares of Common Stock if such conversion would result in the New Lender and its affiliates owning an aggregate of in excess of 49.99% of the then-outstanding shares of Common Stock. Immediately following the execution of the Restated Note, the New Lender elected to convert approximately $3.9 million of outstanding principal into an aggregate of 2,671,633 shares of common stock (the “January Conversion”) having a fair value of approximately $1.7 million. As the January Conversion was exercised by the New Lender in conjunction and in connection with the Debt Consolidation, the two transactions combined were considered a modification of the total debt outstanding with the New Lender (the “New Lender Debt Restructuring”). The New Lender Debt Restructuring was accounted for as a troubled debt restructuring under ASC 470, as 1) the Company was determined to be experiencing financial difficulties as defined by the ASC, and 2) the New Lender Debt Restructuring was deemed to result in a concession by the New Lender. The Company performed a comparison of the undiscounted cash flows associated with the Restructured Note subsequent to the New Lender Debt Restructuring to the carrying value of the Consolidated Notes as of the New Lender Debt Restructuring date. The net carrying value of the Consolidated Notes was determined to exceed the undiscounted future cash flows of the Restated Note after consideration of the January Conversion by approximately $675,000 (the “Excess Carrying Value”). The Restated Note was thus written down to the amount of the undiscounted future cash flows on the Restated Note from the New Lender Restructuring date to maturity. Further, as the New Lender is a related party of the Company, the Excess Carrying Value was accounted for as a capital transaction and no gain or loss was recognized related to the restructuring. GIC Acquisition Note On July 12, 2023, the Board of Directors of the Company approved the issuance of an unsecured promissory note (the “Related Party Note”) in favor of GIC Acquisition, LLC (“GIC”), an entity that is owned and managed by the Company’s Chairman and Chief Executive Officer. Pursuant to the Related Party Note, GIC is obligated to lend up to $0.5 million to the Company, $0.3 million of which was delivered at issuance and the remaining $0.2 million delivered on July 31, 2023. The Related Party Note bears interest at a rate of 10% per annum, will mature in full on August 6, 2023, and may be prepaid without any fee or penalty. The Related Party Note ranks junior to all existing secured indebtedness of the Company. On October 27, 2023, the maturity date of the Related Party Note was subsequently amended to December 31, 2024 at which point principal and accrued interest will be repaid in full. Interest expense incurred on the Related Party Note amounted to approximately $24 thousand for the three months ended March 31, 2024. As of March 31, 2024, the Company has borrowed approximately $1.0 million under the Related Party Note agreement. As of March 31, 2024, future minimum payments on all debt positions were as follows: Years ending December 31 (In thousands), Remaining 2024 $ 2,487 2025 16,938 Total future payments $ 19,426 |
Leases
Leases | 3 Months Ended |
Mar. 31, 2024 | |
Leases [Abstract] | |
Leases | Note 8 — Leases The determination if any arrangement contained a lease at its inception was done based on whether or not the Company has the right to control the asset during the contract period. The lease term was determined assuming the exercise of options that were reasonably certain to occur. Leases with a lease term of 12 months or less at inception were not reflected in the Company’s balance sheet and those lease costs are expensed on a straight-line basis over the respective term. Leases with a term greater than 12 months were reflected as non-current right-of-use assets and current and non-current lease liabilities in the Company’s unaudited condensed consolidated balance sheets. As the implicit interest rate in its leases was generally not known, the Company’s used its incremental borrowing rate as the discount rate for purposes of determining the present value of its lease liabilities. The Company’s incremental borrowing rate was determined using the interest rate on a long term debt position entered into at approximately the same time and for the same duration as the lease. At March 31, 2024 and December 31, 2023, the Company’s weighted-average discount rate utilized for its leases was 7.50% and 7.51%, respectively. When a contract contained lease and non-lease elements, both were accounted for as a single lease component. The Company had several non-cancelable finance leases for machinery and equipment. As of March 31, 2024 the Company had no active finance leases. The Company had several non-cancellable operating leases for corporate offices, warehouses, showrooms, research and development facilities and vehicles. The Company’s leases have remaining lease terms of one year to four years, some of which include options to extend. Some leases include payment for communal area maintenance associated with the property. Additional information on the Company’s operating and financing lease activity was as follows: Three months ended (In thousands) 2024 2023 Operating lease cost $ 130 $ 236 Finance lease cost: Amortization of right-of-use assets — 45 Interest on lease liabilities — 6 Total lease cost $ 130 $ 287 March 31, December 31, Weighted-average remaining lease term – operating leases 2.85 years 3.09 years Weighted-average remaining lease term – finance leases — — Weighted-average discount rate – operating leases 7.50 % 7.51 % Weighted-average discount rate – finance leases — % — % (In thousands) Balance Sheet March 31, December 31, Assets Right-of-use assets, net Right-of-use, net $ 1,651 $ 1,803 Total lease assets $ 1,651 $ 1,803 Liabilities Operating lease liabilities, current Operating lease liabilities, current $ 615 $ 599 Operating lease liabilities, non-current Operating lease liabilities, non-current 1,235 1,394 Total operating lease liabilities $ 1,850 $ 1,993 Maturities of operating lease liabilities as of March 31, 2024 are as follows: Years ending December 31 (In thousands), Operating Remaining 2024 548 2025 748 2026 560 2027 202 Total minimum lease payments 2,058 Less discount (208 ) Total lease liabilities $ 1,850 |
Stockholders_ Deficit
Stockholders’ Deficit | 3 Months Ended |
Mar. 31, 2024 | |
Stockholders’ Deficit [Abstract] | |
Stockholders’ Deficit | Note 9 — Stockholders’ Deficit Public Offerings On February 27, 2024, the Company entered into a placement agency agreement (the “Agency Agreement”) with Alexander Capital, LP as placement agent (the “Placement Agent”), pursuant to which the Company agreed to issue and sell an aggregate of 2,760,000 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 3,963,684 shares of its common stock (the “S-1 Offering”). The public offering price for each share of common stock is $0.38, and the offering price for each Pre-Funded Warrant is $0.379, which equals the public offering price per share of the common stock, less the $0.001 per share exercise price of each Pre-Funded Warrant. The Company issued 67,237 warrants to purchase common stock to Alexander Capital, L.P., referred to as the Placement Agents Warrants above. The warrants were classified as equity warrants and recorded under additional paid-in capital in the unaudited condensed consolidated balance sheets. The warrants have a five-year term and exercise price of 100% of the offering price, and are subject to adjustment for stock splits, reverse stock splits, stock dividends, and similar transactions. The warrants will be exercisable on a cash basis, unless there is not an effective registration statement covering the issuance of the shares issuable upon exercise of the warrants or if shareholder approval for the full exercise of the warrants are not received, in which case the Modified Warrant will also be exercisable on a cashless exercise basis at Alexander Capital election. The measurement of fair value of the Alexander Capital Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $0.52, exercise price of $0.38, term of five years, volatility of 128%, risk-free rate of 4.32%, and expected dividend rate of 0%). The grant date fair value of these Alexander Capital Warrants was estimated to be $31 thousand on February 27, 2024 and is reflected within additional paid-in capital as of March 31, 2024. |
Stock-Based Compensation and Em
Stock-Based Compensation and Employee Benefit Plans | 3 Months Ended |
Mar. 31, 2024 | |
Stock-Based Compensation and Employee Benefit Plans [Abstract] | |
Stock-Based Compensation and Employee Benefit Plans | Note 10 — Stock-Based Compensation and Employee Benefit Plans 2022 Omnibus Equity Incentive Plan On April 29, 2022, the Company’s Board of Directors, and on June 8, 2022, the Company’s stockholders, adopted and approved the 2022 Omnibus Equity Incentive Plan (the “2022 Plan”), which replaced the 2020 Stock Option Plan (the “2020 Plan”). The 2022 Plan provides for the grant of stock options, stock appreciation right awards, performance share awards, restricted stock awards, restricted stock unit awards, other stock-based awards and cash-based awards. The aggregate number of shares of Common Stock that may be reserved and available for grant and issuance under the 2022 Plan is 26,483 shares and 250,000 additional shares issued upon approval by the Board of Directors on January 8, 2024. Shares will be deemed to have been issued under the 2022 Plan solely to the extent actually issued and delivered pursuant to an award. The 2022 Plan shall continue in effect, unless sooner terminated, until the tenth anniversary of the date on which it is adopted by the Board of Directors. As of March 31, 2024, there were 57,719 shares of Common Stock available to be granted under the Company’s 2022 Plan. The Company’s stock compensation expense was $0.5 million and $0.9 million for the three months ended March 31, 2024 and 2023, respectively. Stock Options For the three months ended March 31, 2024, there were no options granted, exercised, forfeited or expired under the Company’s stock option plans. There were 10,310 options outstanding with a weighted average exercise price of $1,595.92 as of March 31, 2024 and December 31, 2023. There were 10,206 options vested and exercisable with a weighted average exercise price of $1,594.66 as of March 31, 2024. There were 10,310 options vested and expected to vest with a weighted average exercise price of $1,595.92 as of March 31, 2024 As of March 31, 2024, total unrecognized compensation expense related to unvested options under the Company’s 2022 Plan was $1.5 thousand, which is expected to be recognized over a weighted average period of years. The following table summarizes information about options vested and exercisable at March 31, 2024: Options Vested and Exercisable Price ($) Number of Options Weighted-Average Weighted-Average Exercise Price $ 456.00 2,884 6.12 $ 456.00 $ 972.00 2,842 6.57 $ 972.00 $ 1,536.00 50 7.00 $ 1,536.00 $ 1,840.00 160 7.75 $ 1,840.00 $ 2,768.00 4,270 6.89 $ 2,768.00 The following table summarizes information about options vested and expected to vest after March 31, 2024: Options Vested and Expected to Vest Price ($) Number of Options Weighted-Average Weighted-Average Exercise Price $ 456.00 2,884 6.12 $ 456.00 $ 972.00 2,856 6.57 $ 972.00 $ 1,536.00 50 7.00 $ 1,536.00 $ 1,840.00 250 7.75 $ 1,840.00 $ 2,768.00 4,270 6.89 $ 2,768.00 Restricted Stock Units The following table presents restricted stock unit activity under the 2022 Plan for the three months ended March 31, 2024: Number of Weighted- Unvested at December 31, 2023 2,136 230.80 Granted 201,938 0.76 Vested (201,955 ) 0.79 Forfeited (284 ) 82.20 Unvested at March 31, 2024 1,835 $ 251.22 As of March 31, 2024, total unrecognized compensation expense related to unvested restricted stock units was $139 thousand, which is expected to be recognized over a weighted average period of 1.12 years. |
Stock Warrants
Stock Warrants | 3 Months Ended |
Mar. 31, 2024 | |
Stock Warrants [Abstract] | |
Stock Warrants | Note 11 — Stock Warrants The following tables present all warrant activity of the Company for the three months ended March 31, 2024: Number of Weighted- Exercise Warrants outstanding at December 31, 2023 5,380,299 $ 10.83 Granted 4,030,921 0.03 Exercised (6,142,217 ) — Forfeited (3,081 ) — Warrants outstanding at March 31, 2024 3,265,922 $ 17.50 The Company received proceeds from the exercise of warrants of $3 thousand for the three months ended March 31, 2024. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2024 | |
Income Taxes [Abstract] | |
Income Taxes | Note 12 — Income Taxes The Company’s effective income tax rate is both 0% for the three months ended March 31, 2024 and 2023, respectively. There were no provisions for (benefits from) income taxes for both years, respectively. There is no difference between the Company’s effective tax rates for the 2024 and 2023 periods. There was no change in the provision for (benefit from) income taxes for the three months ended March 31, 2024 compared to the three months ended March 31, 2023. |
Net Loss Per Share
Net Loss Per Share | 3 Months Ended |
Mar. 31, 2024 | |
Net Loss Per Share [Abstract] | |
Net Loss Per Share | Note 13 — Net Loss Per Share Net (loss) income per share calculations for all periods have been adjusted to reflect the Company’s reverse stock splits. Net (loss) income per share was calculated based on the weighted-average number of the Company’s Common Stock outstanding. Basic net (loss) income per share is calculated using the weighted-average number of Common Stock outstanding during the periods. Diluted net loss per share is computed by giving effect to all potential shares of Common Stock, including convertible notes, outstanding stock options, stock related to unvested restricted stock units, and outstanding warrants to the extent dilutive. Net loss per share, assuming dilution, is equal to basic net loss per share for the three months ended March 31, 2024 and 2023 because the effect of dilutive securities outstanding during the periods, including convertible notes, options, restricted stock units and warrants computed using the treasury stock method, is anti-dilutive. The components of basic and diluted net loss per share were as follows: Three months ended (In thousands, except share and per share data) 2024 (As restated) 2023 Numerator: Numerator for diluted EPS - net (loss) income available to common stockholders after assumed conversions $ 4,533 $ (10,327 ) Effect of dilutive securities: Interest expense on convertible notes $ 297 $ — Numerator for diluted EPS - net (loss) income available to common stockholders after assumed conversions $ 4,533 $ (10,327 ) Denominator: Denominator for basic EPS - weighted-average common stock outstanding 8,894,229 1,072,292 Effect of dilutive securities: Conversion of convertible notes 11,066,376 — Denominator for diluted EPS - adjusted weighted-average common stock outstanding and assumed conversions 19,960,605 1,072,292 Basic net loss (income) per share attributable to common stockholders $ 0.48 $ (9.63 ) Diluted net loss (income) per share attributable to common stockholders $ 0.23 $ (9.63 ) As of March 31, 2024, the Company had convertible notes outstanding with a principal balance of approximately $14.8 million convertible into 10,332,411 shares of Common Stock. During the three months ended March 31, 2024, the Company also converted a portion of the convertible notes into 2,671,633 shares of Common Stock. Given the nominal exercise price of the Company’s issuance of Pre-funded Warrants, such Pre-funded Warrants are included in in the calculation of basic net (loss) income per share and weighted for the period outstanding from issuance to March 31, 2024. The exercise price per warrant is deemed non-substantive when compared to the fair value of the underlying common shares. In determination of the denominator for diluted EPS for the three months ended March 31, 2024, the Company assumed conversion of the 2,671,633 shares of Common Stock as of the beginning of the period, January 1, 2024, eliminating the weighting of the shares from issuance to March 31, 2024. The Company also included in the denominator for diluted EPS for the three months ended March 31, 2024, the assumed conversion of 10,332,411 shares of Common Stock related to the convertible notes. For each of the periods presented, the Company’s potential dilutive securities, which include stock options, restricted stock units, and warrants, have been excluded from the computation of basic and diluted net (loss) income per share with the exception of the Pre-funded Warrants, or penny warrants, which are included in the computation, as detailed above. The weighted-average number of Common Shares outstanding used to calculate both basic and diluted net loss per share attributable to Common Stockholders is the same for the three months ended March 31, 2023. The Company excluded the following potential Common Stock equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to Common Stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three months ended 2024 2023 Shares subject to outstanding stock options 10,206 10,562 Shares subject to unvested restricted stock units 1,835 6,307 Shares subject to outstanding warrants 3,265,922 1,495,001 3,277,963 1,511,870 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2024 | |
Commitments and Contingencies [Abstract] | |
Commitments and Contingencies | Note 14 — Commitments and Contingencies Legal Matters From time to time, the Company may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Bud & Mary’s Litigation On September 15, 2022, the Company provided a notice of default to Bud & Mary’s and certain related parties notifying such parties that Bud & Mary’s was in default of its obligations under the Bud & Mary TTK Agreement. On October 5, 2022, Bud & Mary’s filed a complaint in the Superior Court of Massachusetts in Suffolk County, naming the Company as the defendant. Bud & Mary’s is seeking, among other relief, monetary damages in connection with alleged unfair or deceptive trade practices, breach of contract and conversion arising from the Agreement. While the Company believes the claim is without merit and will continue to vigorously defend itself against Bud & Mary’s allegations, litigation is inherently unpredictable and there can be no assurance that the Company will prevail in this matter. During the third quarter of 2022, the Company deemed it necessary to fully reserve for the outstanding $14.7 million note receivable balance due to the current litigation and the uncertainty of the customer’s ability to repay the balance. The $14.7 million represents the amount of the contingent loss that the Company has determined to be reasonably possible and estimable. The actual cost of resolving this matter may be higher or lower than the amount the Company has reserved. If the Company is unable to realize revenue from its TTK Solution offerings on a timely basis or at all, or if it incurs an additional loss as a result of the Bud & Mary’s claim, the Company’s business and financial performance will be adversely affected. On November 14, 2022, the Company filed its answers and affirmative defenses to the Bud & Mary’s complaint and counterclaims. The Company is seeking, among other relief, monetary damages in connection with the breach of contract, breach of the implied covenant of good faith and fair dealing, unjust enrichment, and enforcement of the guarantees. Bud & Mary’s is permitted to file an amended complaint, and Agrify will be permitted to make responsive filings, which may include an answer and counterclaim. Bowdoin Construction Corp. Litigation On February 22, 2023, Bowdoin Construction Corp. (“Bowdoin”) filed a complaint (the “Bowdoin Complaint”) in the Superior Court of Massachusetts in Norfolk County naming the Company, Bud & Mary’s and certain related parties as defendants, captioned Bowdoin Construction Corp. v. Agrify Corporation, Bud & Mary’s Cultivation, Inc. and BMLC2, LLC, case no. 2382CV00173. The Bowdoin Complaint relates to a construction contract between Bowdoin and the Company relating to the property that is the subject of the Bud & Mary’s Complaint, and alleges breach of contract by Bud & Mary’s and by the Company due to nonpayment of approximately $6.3 million due under the contract and related indemnification claims and mechanics’ liens. The $6.3 million is included in accounts payable in the unaudited condensed consolidated balance sheet. One of Bowdoin’s subs, Hannon Electric, Inc. has filed a separate suit against Agrify in the amount of $1.498 million. The amount is part of the $6.3 million claimed in Bowdoin’s complaint. The Company is entitled to indemnification by Bud & Mary’s and intends to vigorously defend this claim Mack Molding Co. In December 2020, the Company entered into a five-year supply agreement with Mack Molding Co. (“Mack”) pursuant to which Mack will become a key supplier of VFUs. In February 2021, the Company placed a purchase order with Mack amounting to approximately $5.2 million towards the initial production of VFUs during 2021. Since February 2021, the Company increased the purchase order with Mack to approximately $26.5 million towards production of VFUs during 2021 and 2022. The Company believed the supply agreement with Mack would provide the Company with increased scaling capabilities and the ability to meet the potential future demand of its customers more efficiently. The supply agreement contemplates that, following an introductory period, the Company will negotiate a minimum percentage of the VFU requirements that the Company will purchase from Mack each year based on the agreed-upon pricing formula. The introductory period is not time-based but rather refers to the production of an initial number of units after which the parties have rights to adjust pricing and negotiate a certain minimum requirements percentage. The Company believed this approach would result in both parties making a more informed decision with respect to the pricing and other terms of the supply agreement with Mack. On October 11, 2022, the Company received a $9.4 million invoice from Mack for inventory purchased on the Company’s behalf to build VFUs. As part of the terms of the contract manufacturing agreement, Mack had the contractual right to bill the Company for any inventory that had aged greater than nine months. Due to the slowdown in the demand for the VFUs and the lack of a demand forecast that the Company could provide to the vendor, Mack exercised the right to invoice the Company for the slow-moving inventory. As of December 31, 2022, the Company recognized a contingent liability in the amount of $8.4 million, representing an estimate of the amount payable to Mack with respect to the original Mack purchase agreement, and which was included in accounts payable in the unaudited condensed consolidated balance sheet. On March 2, 2023, Mack filed an arbitration action seeking the amounts owed to Mack for purchased inventory. On October 27, 2023, and effective as of October 18, 2023, Mack and the Company entered into a Modification and Settlement Agreement (the “Modification Agreement”) with respect to the dispute rather than engaging in litigation through the courts. On February 29, 2024, the Company met its contractual obligations under the terms of the Modification Agreement. In settlement of the dispute, the Company made cash payments of $500,000 and $250,000 to Mack and issued to Mack a warrant to purchase 750,000 shares of the Company’s Common Stock. In the first quarter of 2024, management derecognized the previously recognized contingent liability, resulting in a credit of approximately $5.9 million, recorded within gain on settlement of contingent liabilities, on the unaudited condensed consolidated statement of operations during the three months ended March 31, 2024. TRC Electronics Litigation The Company was named as a defendant in a complaint filed by TRC Electronics, Inc. (“TRC”) on April 13, 2023 in the United States District Court for the Eastern District of Pennsylvania. In the Complaint, TRC asserts two causes of action against the Company: (1) breach of contract, and (2) promissory estoppel. TRC’s claims are based on allegations that the Company failed to make payments due under three purchase orders for commercial electronics parts. TRC seeks damages in the amount of $565,210, plus attorneys’ fees, costs, and post-judgment interest. The Company has filed an answer denying liability on TRC’s claims and is proceeding with discovery. McCutchan, Inc. In December 2021, the Company entered into a Standard Form of Agreement (“Agreement”) between Owner and Contractor whereby Valiant Group LLC (“Valiant”) is the general contractor for tenant improvements on certain real property located in Bellevue, Washington (the “Project”). McCutchan, Inc. (“McCutchan”) agreed to be a subcontractor on the Project and engaged various other subcontractors. The Company terminated Valiant as the general contractor for, among other allegations, breach of contract and unjust enrichment. Following the termination of Valiant, in October 2022, the Agreement was assigned and accepted (the “Assignment”) to Agxion, LLC, a wholly owned subsidiary of the Company. The Assignment contemplates that, as a subcontractor to the Agreement, McCutchan is still bound to the subcontract agreement and will continue construction operations on the Project. The Company is pursuing Valiant in a separate litigation (the “Valiant Litigation”) to collect no less than approximately $1.4 million alleging overbilling, breach of the Agreement, and violation of Chapter 18.27 and 19.86 RCW in Washington. On March 5, 2024, McCutchan, Inc. (“McCutchan”) filed a complaint in the Superior Court of Washington for King County naming the Company, Valiant, and certain related parties as defendants. In the Complaint, McCutchan asserts two causes of action against the Company: (1) breach of contract, (2) voidable contract, (3) interference with business or economic expectancy, (4) unjust enrichment, and (5) defamation. McCutchan’s claims are based on allegations of misrepresentations made by the Company to pay McCutchan for work completed on the Project as well as a failure to pay under the Agreement. In the alternative, McCutchan is alleging the Assignment is void and not a valid contract. McCutchan is seeking to collect no less than $3 million against the Company and all other named defendants. The Company, Valiant, and McCutchan have all agreed to mediate the matter. McCutchan has asked to postpone the original scheduled May 7 th Valiant Group LLC Agrify filed a separate complaint against Valiant for overbilling, misrepresentation, and breach for the Treehouse project in Nevada. Valiant has failed to respond and Agrify has since submitted an entry of default to the court and is currently seeking for award in the amount of $1.5 million. However, there is no guarantee that the Court would award the full amount and no guarantee that Agrify would be able to successfully collect the full amount from Valiant. Other Litigation In September 2023, the Company settled a legal dispute with a specific customer which resulted in the recognition of a gain of approximately $0.9 million, of which $0.3 million was paid in October 2023, with the remaining approximate $0.6 million to be paid in equal monthly installments, beginning in January, 2024. This gain was recognized as part of other income, net per the unaudited condensed consolidated statement of operations for the three months ended March 31, 2024, with the approximate $0.9 million receivable balance recognized as part of prepaid expenses and other current assets, per the unaudited condensed consolidated balance sheet, as of March 31, 2024. The settlement also resulted in the return of equipment to the Company in October 2023. The Company is currently pursuing 10 separate legal proceedings in attempting to collect approximately $2.5 million outstanding receivables. The Company is not confident that all legal proceedings and collection efforts will yield in positive results or return of equipment. On April 25, 2024, Medical Investor Holdings, LLC dba Vertical Companies (“MIH”) filed a complaint against Agrify demanding $288,000. MIH purchased an XMU hydrocarbon extraction system from Precision in October 2021. MIH chose to not include installation and training in the original purchase but is now having problems with this equipment. The Company this is a meritless case. The Company is also a defendant or plaintiff in a variety of other litigation matters that are individually insignificant. The timing and amount of any settlements, including potential payments made or received, is uncertain. Nonetheless, management currently estimates that the Company’s aggregate net loss exposure with respect to these cases is within the range of approximately $150,000 to $300,000. On July 2022, claimant, an ex-sales VP is claiming he is owed back wages, commission and is entitled to equity in the company, under theories of liability under Massachusetts labor laws including retaliation, breach of contract, breach of covenant of good faith and fair dealing, fraudulent inducement, tortious interference & unjust enrichment. Company has filed its answer to the initial complaint in January 2023. The Company believes this is a meritless case and has responded to various discovery requests. Commitments Mack Molding Co. The Modification Agreement with Mack referenced above resulted in the Company entering a purchase commitment with Mack where it is contractually obligated to purchase a minimum of 25 VFUs per quarter for each quarter during 2024 and a minimum of 50 VFUs per quarter for the six quarters beginning with the first quarter of 2025, at a per VFU price of $14,000. The Company made payment and took collection of 25 VFUs in the second quarter of 2024. The Company has also granted Mack a second lien position on all Agrify assets. The Company is also required to pay a storage fee of $25,000 to Mack, per month, for VFU parts subject to the Modification Agreement. Other Commitments and Contingencies The Company is potentially subject to claims related to various non-income taxes (such as sales, value-added, consumption, and similar taxes) from various tax authorities, including in jurisdictions in which the Company already collects and remits such taxes. If the relevant taxing authorities successfully pursue these claims, the Company could be subject to additional tax liabilities. Refer to Note 7 – Debt, included elsewhere in the notes to the unaudited condensed consolidated financial statements for details of the Company’s future minimum debt payments. Refer to Note 8 – Leases, included elsewhere in the notes to the unaudited condensed consolidated financial statements for details of the Company’s future minimum lease payments under operating and financing lease liabilities. Refer to Note 12 – Income Taxes, included elsewhere in the notes to the unaudited condensed consolidated financial statements for information regarding income tax contingencies. |
Related Parties
Related Parties | 3 Months Ended |
Mar. 31, 2024 | |
Related Parties [Abstract] | |
Related Parties | Note 15 — Related Parties Some of the officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities that become available. The following table describes the net purchasing (sales) activity with entities identified as related parties to the Company: Three months ended (In thousands) 2024 2023 Bluezone $ — $ 4 Topline Performance Group — (1 ) NEIA — (43 ) Greenstone Holdings — (2 ) The following table summarizes net related party (payable) receivable as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Bluezone $ — $ (4 ) Valiant Americas, LLC — 1 On July 12, 2023, the Company issued an unsecured promissory note in favor of GIC Acquisition, LLC, an entity that is owned and managed by the Company’s Chairman and Chief Executive Officer. Refer to Note 7 - Debt for further disclosure related to this Related Party Note. On October 27, 2023, CP Acquisitions LLC, an entity affiliated with and controlled by Company’s Chairman and Chief Executive Officer, purchased the Exchange Note and the Convertible Note. In addition, the Company issued to CP a Junior Secured Note. Refer to Note 7 - Debt for further disclosure related to this Related Party Note. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2024 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 16 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Exercise of Company Issued Prefunded Warrants In April 2024, a holder of 953,684 of the Company’s previously issued prefunded warrants exercised such warrants for the purchase of 953,684 of the Company’s common stock. Cash Contributions CP Acquisitions LLC made cash contributions to the Company from the ongoing CP note payable, in the amounts of $350 thousand and $175 thousand on July 24, 2024 and August 7, 2024, respectively. |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Pay vs Performance Disclosure | ||
Net Income (Loss) | $ 4,236 | $ (10,327) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Mar. 31, 2024 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 3 Months Ended |
Mar. 31, 2024 | |
Overview, Basis of Presentation and Significant Accounting Policies [Abstract] | |
Description of Business | Description of Business Agrify Corporation (“Agrify” or the “Company”) is a provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. The Company’s proprietary micro-environment-controlled Agrify Vertical Farming Units (or “VFUs”) enable cultivators to produce the highest quality products with what we believe to be unmatched consistency, yield, and return investment at scale. The Company’s comprehensive extraction product line, which includes hydrocarbon, alcohol, solventless, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates. The Company was formed in the State of Nevada on June 6, 2016 as Agrinamics, Inc., and subsequently changed its name to Agrify Corporation. The Company is sometimes referred to herein by the words “we,” “us,” “our,” and similar terminology. The Company has nine wholly-owned subsidiaries, which are collectively referred to as the “Subsidiaries” and the Company also has ownership interests in certain companies. |
Nasdaq Deficiency Notice | Nasdaq Deficiency Notice The Nasdaq Notice had no immediate effect on the listing of the Company’s Common Stock on The Nasdaq Stock Market LLC. On October 17, 2023, the Company received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of Nasdaq notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Listing Rule as a result of its failure to file the First Quarter Form 10-Q, the Second Quarter Form 10-Q and the Form 10-K (collectively, the “Delinquent Reports”) in a timely manner. On November 16, 2023, the Company received a notice from Nasdaq that the Company remains noncompliant with the Listing Rule as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 with the SEC by the required filing date. On December 1, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company reported stockholders’ deficit of $(17.17) million in its Form 10-Q for the quarter ended March 31, 2023, the Company was no longer in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Primary Equity Listing Rule”), which requires that listed companies maintain a minimum of $2.5 million in stockholders’ equity. In response, the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”), which stayed any further action by the Listing Qualifications Staff. The hearing was held on January 11, 2024. The Company arrived at the hearing having previously cured any additional grounds for delisting as a result of delinquent periodic filings during 2023 that were filed prior to the hearing. On January 30, 2024, the Company received formal notice that the Panel had granted the Company’s request for an exception through April 15, 2024 to evidence compliance with the Listing Rule, which was subsequently extended to May 15, 2024. Accordingly, there can be no assurance that the Company will be able to regain compliance with the Nasdaq listing rules or maintain its listing on the Nasdaq Capital Market. If the Company’s common stock is delisted, it could be more difficult to buy or sell the Company’s common stock or to obtain accurate quotations, and the price of the Company’s common stock could suffer a material decline. Delisting could also impair the Company’s ability to raise capital. On March 5, 2024, the Company received a deficiency letter from the Staff of Nasdaq notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq Stock Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. The compliance period for the Company will expire on September 3, 2024. |
Restatement of Previously Issued Quarterly Condensed Consolidated Financial Statements for the Three Months Ended March 31, 2024 | Restatement of Previously Issued Quarterly Condensed Consolidated Financial Statements for the Three Months Ended March 31, 2024 As further described below, our unaudited condensed consolidated financial statements covering the quarterly reporting period ended March 31, 2024 have been revised to reflect the correction of errors. Restatement Background The need for the restatement arose out of the results of certain reassessment by the Company of the accounting for the settlement agreement entered into by the Company with Mack Molding Co which became effective in the first quarter of 2024 (See Note 14 - Commitments and Contingencies). Management determined that the gain from the derecognized contingent liability should be recognized fully in Q1, rather than over time as previously reported. Consequently, the Company concluded that the accounting treatment applied in the first quarter of 2024 was not appropriate. Therefore, the Company misstated inventory, accounts payable, notes payable, accumulated deficit and total stockholders’ equity (deficit), on the face of the unaudited condensed consolidated balance sheet as of March 31, 2024, and cost of goods sold, general and administrative expenses, gain on settlement of contingent liabilities, and interest income (expense), net, on the unaudited condensed consolidated statement of operations, for the three months ended March 31, 2024. The Company principally attributes the errors to a material weakness in internal controls over financial reporting, as disclosed in Item II, Part 9A of this Annual Report on Form 10-K. The Company has commenced procedures to remediate the material weaknesses. However, these material weaknesses will not be considered remediated until the applicable remedial actions have been fully implemented and the Company has concluded that these controls are operating effectively for a sufficient period of time. Restatement Adjustments The following tables summarizes the effect of the errors on the Company’s unaudited condensed consolidated balance sheet as of March 31, 2024 and unaudited condensed consolidated statement of operations and unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2024: March 31, Adjustment March 31, Inventory $ 18,862 $ (214 ) $ 18,648 Accounts payable 12,428 350 12,778 Notes payable, current $ 1,374 $ (1,374 ) $ — Notes payable, net of current 3,464 (3,464 ) — Accumulated deficit (265,835 ) 4,274 (261,561 ) Total stockholders’ equity (deficit) (9,725 ) 4,274 (5,451 ) Three Adjustment Three Cost of goods sold $ 1,869 $ 564 $ 2,433 Gross profit 729 (564 ) 165 General and administrative 2,952 1,142 4,094 Gain on settlement of contingent liabilities — (5,935 ) (5,935 ) Operating (loss) income (780 ) 4,229 3,449 Interest income (expense), net (145 ) 45 (100 ) Net (loss) income (38 ) 4,274 4,236 Basic $ 0.00 $ 0.48 $ 0.48 Diluted $ 0.00 $ 0.23 $ 0.23 While the adjustments changed net loss, gain on supply agreement, gain on revaluation of contingent liability, gain on settlement of contingent liabilities, inventory, and accounts payable line items in the unaudited condensed consolidated cash flow statement, they did not have an impact on total net cash used in operating activities, net cash used in investing activities, or net cash provided by financing activities. Three Adjustment Three Cash flows from operating activities Net loss $ (38 ) $ 4,274 $ 4,236 Adjustments to reconcile net loss to net cash used in operating activities: Gain on supply agreement (1,142 ) 1,142 — Gain on revaluation of contingent liability (564 ) 564 — Gain on settlement of contingent liabilities — (5,935 ) (5,935 ) Changes in operating assets and liabilities Inventory 1,211 (350 ) 861 Accounts payable (2,361 ) 305 (2,056 ) Net cash used in operating activities $ (2,987 ) $ — $ (2,987 ) The related notes to the unaudited condensed consolidated financial statements have also been restated to reflect the error corrections described above. |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and Principles of Consolidation These interim unaudited condensed consolidated financial statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring accruals) and disclosures necessary for a fair presentation of these interim unaudited condensed consolidated financial statements have been included. The results reported in the unaudited condensed consolidated financial statements for any interim periods are not necessarily indicative of the results that may be reported for the entire year. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and do not include all information and footnotes necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on April 15, 2024. Accounting for Wholly-Owned Subsidiaries The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of Agrify Corporation and its wholly-owned subsidiaries, as described above, in accordance with the provisions required by the Consolidation Topic 810 of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The Company includes results of operations of acquired companies from the date of acquisition. All significant intercompany transactions and balances are eliminated. Accounting for Less Than Wholly-Owned Subsidiaries For the Company’s less than wholly-owned subsidiaries, which include, Agrify-Valiant LLC (“Agrify-Valiant”), and Agrify Brands, LLC (“Agrify Brands”), the Company first analyzes whether these entities are a variable interest entity (a “VIE”) in accordance with ASC Topic 810, Consolidation Based on the Company’s analysis of these entities, the Company has determined that Agrify-Valiant and Agrify Brands are each a VIE, and that the Company is the primary beneficiary. While the Company owns 60% of Agrify-Valiant’s equity interests and 75% of Agrify Brand’s equity interests, the remaining equity interests in Agrify-Valiant and Agrify Brands are owned by unrelated third parties, and the agreement with these third parties provides the Company with greater voting rights. Accordingly, the Company consolidates its interest in the financial statements of Agrify-Valiant and Agrify Brands under the VIE rules and reflects the third parties’ interests in the consolidated financial statements as a non-controlling interest. The Company records this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. These non-controlling interests are not redeemable by the equity holders and are presented as part of permanent equity. Income and losses are allocated to the non-controlling interest holders based on its economic ownership percentage. |
Going Concern | Going Concern In accordance with the FASB Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements - Going Concern The Company has incurred operating losses since its inception and has negative cash flows from operations and a working capital deficit. The Company also has an accumulated deficit of $261.6 million as of March 31, 2024. The Company’s primary sources of liquidity are its cash and cash equivalents and marketable securities, with additional liquidity accessible, subject to market conditions and other factors, including limitations that may apply to the Company under applicable SEC regulations, from the capital market. As of March 31, 2024, the Company had $0.1 million of cash, cash equivalents, and marketable securities. The Company had no restricted cash as of March 31, 2024. Current liabilities were $26.7 million as of March 31, 2024. These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company believes these conditions raise substantial doubt about its ability to continue as a going concern within the next twelve-months from the date these unaudited condensed consolidated financial statements are available to be issued. The Company’s continuation as a going concern is dependent upon its ability to obtain the necessary debt or equity financing to continue operations until the Company begins generating sufficient cash flows from operations to meet its obligations. If the Company is unable raise additional funds, it may be forced to cease operations. On February 28, 2024, the company raised net proceeds of $2.2 million via the issuance of common stock and prefunded warrants in a public offering through Alexander Capital and is recorded within common stock and additional paid-in capital on the Company’s unaudited condensed consolidated balance sheet. The Company intends to raise additional capital later this year to support its 2024 and 2025 funding needs. The Company also continues to make additional adjustments in headcount, salary, travel, sales and marketing spending, but there is no guarantee that these ongoing cost-cutting efforts or capital raises will be sufficient to maintain operations. There is no assurance that the Company will ever be profitable. The unaudited condensed consolidated financial statements do not include any adjustments to reflect the potential future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. |
Use of Estimates | Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates include assumptions about collection of accounts and loans receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets, the valuation of inventory, and useful life of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific information, other relevant factors that it believes to be reasonable under the circumstances, and management’s judgement. On an ongoing basis, the Company evaluates its estimates when there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual financial results could differ from those estimates. The Company regularly evaluates its assets, including asset groups or reporting units, for impairment in accordance with U.S. GAAP. The Company is aware of the impact that prolonged net losses can have on the fair value of underlying assets and the overall company. The Company is committed to ensuring that the carrying amounts of its assets are appropriately assessed and adjusted for any impairment, reflecting a true and fair view of its financial position. |
Accounts Receivable, Net and Loan Receivable, Net | Accounts Receivable, Net and Loans Receivable, Net Accounts receivable, net, primarily consists of amounts for goods and services that are billed and currently due from customers. The composition of loan receivable, net is detailed in Note 5 - Loans Receivable. In accordance with ASC 310-10, accounts receivable and loan receivable balances are presented net of an allowance for credit losses, which are an estimate of billed or borrowed amounts that may not be collectible. In determining the amount of the allowance at each reporting date, management makes judgments about general economic conditions, historical write-off experience, and any specific risks identified in customer or borrower collection matters, including the aging of unpaid accounts receivable and changes in customer or borrower financial conditions. Accounts and loans receivable balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for credit losses are recorded as general and administrative expenses in the consolidated statements of operations. |
Concentration of Credit Risk and Significant Customer | Concentration of Credit Risk and Significant Customer Financial instruments that potentially subject the Company to a concentration of credit risk primarily consist of cash, cash equivalents, marketable securities, accounts receivable, and loans receivable. Cash equivalents primarily consist of money market funds with original maturities of three months or less, which are invested primarily with U.S. financial institutions. Cash deposits with financial institutions generally exceed federally insured limits. Management believes minimal credit risk exists with respect to these financial institutions and the Company has not experienced any losses on such amounts. During the year three -month period ended March 31, 2024, the Company has one customer that comprised approximately 1% of its revenue and two customers that comprised approximately 47% of its accounts receivable balance. During the year three -month period ended March 31, 2023, the Company has one customer that comprised approximately 11% of its revenue and two customers that comprised approximately 84% of it accounts receivable balance. |
Inventories | Inventories The Company values all its inventories, which consist primarily of significant raw material hardware components, at the lower of cost or net realizable value, with cost principally determined by the weighted-average cost method on a first-in, first-out basis. Write-offs of potentially slow-moving or damaged inventory are recorded through specific identification of obsolete or damaged material. The Company takes a physical inventory count at least once annually at all inventory locations. |
Property and Equipment | Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expenses are recognized using the straight-line method over the estimated useful life of each asset, as follows: Estimated Useful Life (Years) Computer and office equipment 2 to 3 Furniture and fixtures 2 Software 3 Vehicles 5 Research and development of laboratory equipment 5 Machinery and equipment 3 to 5 Leased equipment 5 to 13 Trade show assets 3 to 5 Leasehold improvements Lower of estimated useful life or remaining lease term The estimated useful lives of the Company’s property and equipment are periodically assessed to determine if changes are appropriate. The Company charges maintenance and repairs to expense as incurred. When the Company retires or disposes of assets, the carrying cost of these assets and related accumulated depreciation or amortization are eliminated from the condensed consolidated balance sheets and any resulting gain or loss is included in the condensed consolidated statements of operations in the period of retirement or disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. During construction, costs are accumulated in a construction-in-progress account, with no depreciation. Upon completion, costs are transferred to the appropriate asset account, and depreciation begins when the asset is placed into service. |
Warrant Liabilities | Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all its financial instruments, including issued private placement stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 480, Distinguishing Liabilities from Equity For issued or modified warrants that meet all of the criteria for equity classification, they are recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that are precluded from equity classification, they are recorded as a liability at their initial fair value on the date of issuance and subject to remeasurement on each balance sheet date with changes in the estimated fair value of the warrants to be recognized as an unrealized gain or loss in the unaudited condensed consolidated statements of operations. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company’s financial instruments consist of cash, marketable securities, accounts receivable, accounts payable, accrued expenses, warrant liabilities, and loans receivable. Refer to Note 4 - Fair Value Measures, included elsewhere in the notes to the unaudited condensed consolidated financial statements for details of the Company’s financial instruments. |
Revenue Recognition | Revenue Recognition Overview The Company generates revenue from the following sources: (1) equipment sales, (2) providing services and (3) construction contracts. In accordance with ASC 606 Revenue Recognition ● identify the customer contract; ● identify performance obligations that are distinct; ● determine the transaction price; ● allocate the transaction price to the distinct performance obligations; and ● recognize revenue as the performance obligations are satisfied. Identify the customer contract A customer contract is generally identified when there is approval and commitment from both the Company and its customer, the rights have been identified, payment terms are identified, the contract has commercial substance and collectability is probable. Specifically, the Company obtains written/electronic signatures on contracts and purchase orders, if said purchase orders are issued in the normal course of business by the customer. Identify performance obligations that are distinct A performance obligation is a promise by the Company to provide a distinct good or service or a series of distinct goods or services. A good or service that is promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer, and a company’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determine the transaction price The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer, excluding sales taxes that are collected on behalf of government agencies. Allocate the transaction price to distinct performance obligations The transaction price is allocated to each performance obligation based on the relative standalone selling prices (“SSP”) of the goods or services being provided to the customer. The Company’s contracts typically contain multiple performance obligations, for which the Company accounts for individual performance obligations separately, if they are distinct. The standalone selling price reflects the price the Company would charge for a specific piece of equipment or service if it was sold separately in similar circumstances and to similar customers. Recognize revenue as the performance obligations are satisfied Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer. Significant Judgments The Company enters into contracts that may include various combinations of equipment, services and construction, which are generally capable of being distinct and accounted for as separate performance obligations. Contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Once the Company determines the performance obligations, it determines the transaction price, which includes estimating the amount of variable consideration to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on the SSP. The corresponding revenue is recognized as the related performance obligations are satisfied. Judgment is required to determine the SSP for each distinct performance obligation. The Company determines SSP based on the price at which the performance obligation is sold separately and the methods of estimating SSP under the guidance of ASC 606-10-32-33. If the SSP is not observable through past transactions, the Company estimates the SSP, taking into account available information such as market conditions, expected margins, and internally approved pricing guidelines related to the performance obligations. The Company licenses its software as a service (“SaaS”) type subscription license, whereby the customer only has a right to access the software over a specified time period. The full value of the contract is recognized ratably over the contractual term of the SaaS subscription, adjusted monthly if tiered pricing is relevant. The Company typically satisfies its performance obligations for equipment sales when equipment is made available for shipment to the customer; for services sales as services are rendered to the customer and for construction contracts both as services are rendered and when the contract is completed. The Company utilizes the cost-plus margin method to determine the SSP for equipment and build-out services. This method is based on the cost of the services from third parties, plus a reasonable markup that the Company believes is reflective of a market-based reseller margin. The Company determines the SSP for services in time and materials contracts by observable prices in standalone services arrangements. The Company estimates variable consideration in the form of royalties, revenue share, monthly fees, and service credits at contract inception and updated at the end of each reporting period if additional information becomes available. Variable consideration is typically not subject to constraint. Changes to variable consideration were not material for the periods presented. If a contract has payment terms that differ from the timing of revenue recognition, the Company will assess whether the transaction price for those contracts include a significant financing component. The Company has elected the practical expedient that permits an entity to not adjust for the effects of a significant financing component if the Company expects that at the contract inception, the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service, will be one year or less. For those contracts in which the period exceeds the one-year threshold, this assessment, as well as the quantitative estimate of the financing component and its relative significance, requires judgment. Accordingly, the Company imputes interest on such contracts at an agreed-upon interest rate and will present the financing components separately as financial income. As of March 31, 2024 and March 31, 2023, the Company did not have any such financial income. Payment terms with customers typically require payment 30 days from the invoice date. The Company’s agreements with its customers do not provide for any refunds for services or products and therefore no specific reserve for such is maintained. In the infrequent instances where customers raise concern over delivered products or services, the Company has endeavored to remedy the concern and all costs related to such matters have been insignificant in all periods presented. The Company has elected to treat shipping and handling activities after the customer obtains control of the goods as a fulfillment cost and not as a promised good or service. Accordingly, the Company will accrue all fulfillment costs related to the shipping and handling of consumer goods at the time of shipment. The Company has payment terms with its customers of one year or less and has elected the practical expedient applicable to such contracts not to consider the time value of money. Sales, value add, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company receives payment from customers based on specified terms that are generally less than 30 days from the satisfaction of performance obligations. There are no contract assets related to performance under the contract. The difference in the opening and closing balances of the Company’s contract liabilities primarily results from the timing difference between the Company’s performance and the customer’s payment. The Company fulfills obligations under a contract with a customer by transferring products and services in exchange for consideration from the customer. Accounts receivable are recorded when the customer has been billed or the right to consideration is unconditional. The Company recognizes a contract liability when consideration has been received or an amount of consideration is due from the customer, and the Company has a future obligation to transfer certain proprietary products. In accordance with ASC 606-10-50-13, the Company is required to include disclosure on its remaining performance obligations as of the end of the current reporting period. Due to the nature of the Company’s contracts, these reporting requirements are not applicable. The majority of the Company’s remaining contracts meet certain exemptions as defined in ASC 606-10-50-14 through 606-10-50-14A, including (i) performance obligation is part of a contract that has an original expected duration of one year or less and (ii) the right to invoice practical expedient. The Company generally provides a one-year warranty on its products for materials and workmanship but may provide multiple year warranties as negotiated, and generally transfers to its customers the warranties it receives from its vendors, if any, which generally cover this one-year period. In accordance with ASC 450-20-25, the Company accrues for product warranties when the loss is probable and can be reasonably estimated. The Company maintained a reserve for warranty returns of $0.4 million and $0.4 million as of March 31, 2024 and December 31, 2023, respectively. The Company’s reserve for warranty returns is included in accrued expenses and other current liabilities in its unaudited condensed consolidated balance sheets. Additional information regarding the Company’s warranty reserve may be found in Note 3 – Supplemental Consolidated Balance Sheet Information, included elsewhere in the notes to the unaudited condensed consolidated financial statements. |
Research and Development Costs | Research and Development Costs The Company expenses research and development costs as incurred. Research and development expenses include payroll, employee benefits and other expenses associated with product development. The Company incurs research and development costs associated with the development and enhancement of both hardware and software products associated with its cultivation and extraction equipment, as well as its SaaS-based software offering, Agrify Insights™ cultivation software (“Agrify Insights™”). |
Net Loss Per Share | Net Loss Per Share The Company presents basic and diluted net (loss) income per share attributable to common stockholders in conformity with the one-class method. The Company computes basic (loss) income per share by dividing net (loss) income available to common stockholders by the weighted-average number of common stock outstanding. Diluted (loss) income per share adjusts basic (loss) income per share for the potentially dilutive impact of convertible notes, stock options, restricted stock units and warrants. As the Company has reported losses for the three months ended March 31, 2023, all potentially dilutive securities including convertible notes, stock options, restricted stock units and warrants, are anti-dilutive, and accordingly, basic net loss per share equals diluted net loss per share for that period. For the three months ended March 31, 2024, the Company adjusts the net income available to common stockholders and the weighted average common stock outstanding for the effect of dilutive securities as presented within Note 13 — Net (Loss) Income Per Share. Net loss per share calculations for all periods have been adjusted to reflect the reverse stock split effected on July 5, 2023. Net loss per share was calculated based on the weighted-average number of common stock outstanding. |
Recently Announced Accounting Pronouncements | Recently Announced Accounting Pronouncements On December 14, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures Other recent accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future condensed consolidated financial statements. |
Overview, Basis of Presentati_2
Overview, Basis of Presentation and Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Overview, Basis of Presentation and Significant Accounting Policies [Abstract] | |
Schedule of Effect of The Errors on the Company’s Consolidated Balance Sheet | The following tables summarizes the effect of the errors on the Company’s unaudited condensed consolidated balance sheet as of March 31, 2024 and unaudited condensed consolidated statement of operations and unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2024: March 31, Adjustment March 31, Inventory $ 18,862 $ (214 ) $ 18,648 Accounts payable 12,428 350 12,778 Notes payable, current $ 1,374 $ (1,374 ) $ — Notes payable, net of current 3,464 (3,464 ) — Accumulated deficit (265,835 ) 4,274 (261,561 ) Total stockholders’ equity (deficit) (9,725 ) 4,274 (5,451 ) |
Schedule of Consolidated Statement of Operations | Three Adjustment Three Cost of goods sold $ 1,869 $ 564 $ 2,433 Gross profit 729 (564 ) 165 General and administrative 2,952 1,142 4,094 Gain on settlement of contingent liabilities — (5,935 ) (5,935 ) Operating (loss) income (780 ) 4,229 3,449 Interest income (expense), net (145 ) 45 (100 ) Net (loss) income (38 ) 4,274 4,236 Basic $ 0.00 $ 0.48 $ 0.48 Diluted $ 0.00 $ 0.23 $ 0.23 |
Schedule of Consolidated Statement of Cash Flows | Three Adjustment Three Cash flows from operating activities Net loss $ (38 ) $ 4,274 $ 4,236 Adjustments to reconcile net loss to net cash used in operating activities: Gain on supply agreement (1,142 ) 1,142 — Gain on revaluation of contingent liability (564 ) 564 — Gain on settlement of contingent liabilities — (5,935 ) (5,935 ) Changes in operating assets and liabilities Inventory 1,211 (350 ) 861 Accounts payable (2,361 ) 305 (2,056 ) Net cash used in operating activities $ (2,987 ) $ — $ (2,987 ) |
Schedule of Property and Equipment Estimated Useful Life | Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expenses are recognized using the straight-line method over the estimated useful life of each asset, as follows: Estimated Useful Life (Years) Computer and office equipment 2 to 3 Furniture and fixtures 2 Software 3 Vehicles 5 Research and development of laboratory equipment 5 Machinery and equipment 3 to 5 Leased equipment 5 to 13 Trade show assets 3 to 5 Leasehold improvements Lower of estimated useful life or remaining lease term |
Revenue and Contract Liabilit_2
Revenue and Contract Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Revenue and Contract Liabilities [Abstract] | |
Schedule of Revenue Disaggregated by the Timing of Revenue Recognition | The following table provides the Company’s revenue disaggregated by the timing of revenue recognition: Three months ended (In thousands) 2024 2023 Transferred at a point in time $ 2,465 $ 4,920 Transferred over time 133 884 Total revenue $ 2,598 $ 5,804 |
Schedule of Current Deferred Revenue | Changes in the Company’s current contract liabilities balance for the three months ended March 31, 2024 and the year ended December 31, 2023 were as follows: (In thousands) Three Year Contract liabilities – beginning of period $ 4,019 $ 4,112 Additions 1,160 4,905 Recognized (1,395 ) (4,998 ) Contract liabilities – end of period $ 3,784 $ 4,019 |
Supplemental Condensed Consol_2
Supplemental Condensed Consolidated Balance Sheet Information (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Supplemental Consolidated Balance Sheet Information [Abstract] | |
Schedule of Accounts Receivable | Accounts receivable consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Accounts receivable, gross $ 2,723 $ 3,036 Less allowance for credit losses (2,512 ) (1,887 ) Accounts receivable, net $ 211 $ 1,149 |
Schedule of Allowance for Credit Losses Accounts | The changes in the allowance for credit losses accounts consisted of the following: (In thousands) Three Year Allowance for credit losses - beginning of period $ 1,887 $ 4,605 (Recovery of) allowance for credit losses 642 (1,426 ) Accounts receivable written-off (17 ) (1,292 ) Allowance for credit losses - end of period $ 2,512 $ 1,887 |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses and other current assets consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Other receivables, other $ 536 $ 659 Prepaid insurance 352 454 Prepaid expenses, other 93 82 Prepaid software 31 70 Prepaid materials 16 13 Prepaid settlement asset — 2,054 Total prepaid expenses and other current assets $ 1,028 $ 3,332 |
Schedule of Property and Equipment | Property and equipment, net consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Leased equipment $ 4,465 $ 4,465 Leasehold improvements 702 702 Machinery and equipment 904 904 Software 606 606 Computer and office equipment 588 588 Research and development laboratory equipment 183 183 Furniture and fixtures 116 116 Trade show assets 78 78 Vehicles 43 43 Total property and equipment, gross 7,685 7,685 Accumulated depreciation (3,300 ) (2,894 ) Construction in progress 2,943 2,943 Total property and equipment, net $ 7,328 $ 7,734 |
Schedule of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Sales tax payable (1) $ 5,320 $ 5,338 Accrued construction costs 1,312 1,412 Accrued professional fees 423 457 Accrued warranty expenses 415 420 Compensation related fees 313 474 Accrued consulting fees 45 43 Accrued interest expense 12 321 Accrued inventory purchases 3 10 Accrued acquisition liabilities — 2,180 Total accrued expenses and other current liabilities $ 7,843 $ 10,655 (1) Sales tax payable primarily represents identified sales and use tax liabilities arising from our acquisition of Precision and Cascade. These amounts are included as part of our initial purchase price allocations and are the subject matter of an indemnification claim under the Precision and Cascade acquisition agreement. |
Fair Value Measures (Tables)
Fair Value Measures (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Fair Value Measures [Abstract] | |
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis | At March 31, 2024 and December 31, 2023, the Company’s assets and liabilities measured at fair value on a recurring basis were as follows: March 31, 2024 December 31, 2023 Fair Value Measurements Using Input Types Fair Value Measurements Using Input Types (In thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Money market funds 4 — — 4 4 — — 4 Total assets $ 4 $ — $ — $ 4 $ 4 $ — $ — $ 4 Liabilities: Warrant liabilities - January 2022 warrants $ — $ — $ — $ — $ — $ — $ 1 $ 1 Warrant liabilities - March 2022 warrants — — 1 1 — — 7 7 Warrant liabilities - August 2022 warrants — — 3 3 — — 18 18 Warrant liabilities - December 2022 warrants — — 413 413 — — 1,264 1,264 Total liabilities $ — $ — $ 417 $ 417 $ — $ — $ 1,290 $ 1,290 |
Schedule of Company’s Assumptions Used in the Valuations | The following table summarizes the Company’s assumptions used in the valuations as of March 31, 2024 and December 31, 2023: January March August December January March August December March 31, 2024 December 31, 2023 Stock price $ 0.37 $ 0.37 $ 0.37 $ 0.37 $ 1.26 $ 1.26 $ 1.26 $ 1.26 Exercise price $ 1,496 $ 430 $ 246 $ 0.38 $ 1,496 $ 430 $ 246 $ 3.45 Expected term (in Years) 3.32 3.88 3.88 3.88 3.57 4.13 4.13 4.13 Volatility 136.00 % 138.00 % 138.00 % 138.00 % 138.00 % 136.00 % 136.00 % 136.00 % Discount rate - treasury yield 4.37 % 4.32 % 4.32 % 4.32 % 3.96 % 3.91 % 3.91 % 3.91 % |
Schedule of Changes in the Fair Value of the Level 3 Warrant Liabilities | The following table sets forth a summary of the changes in the fair value of the Level 3 warrant liabilities for the three months ended March 31, 2024 and for the year ended December 31, 2023: (In thousands) March 31, For the Warrant liabilities – beginning of period $ 1,290 $ 5,985 Change in estimated fair value (873 ) (4,695 ) Warrant liabilities –end of period $ 417 $ 1,290 |
Loans Receivable (Tables)
Loans Receivable (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Loans Receivable [Abstract] | |
Schedule of Breakdown of Loans Receivable by Customer | The breakdown of loans receivable by customer as of March 31, 2024 and December 31, 2023 were as follows: (In thousands) March 31, December 31, Customer 139 $ 14,361 $ 14,691 Customer 125 9,297 9,297 Customer 24096 6,810 6,810 Allowance for credit losses (18,885 ) (19,215 ) Total loan receivable, net of allowance for credit losses $ 11,583 $ 11,583 Less: current portion (692 ) — Total loan receivable, net of current $ 10,891 $ 11,583 |
Inventory (Tables)
Inventory (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Inventory [Abstract] | |
Schedule of Inventory | Inventory consisted of the following as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Raw materials $ 22,392 $ 23,449 Prepaid inventory 816 924 Finished goods 7,848 7,438 Inventory for resale 4,776 4,882 Inventory, gross 35,832 36,693 Inventory reserves (17,184 ) (17,599 ) Total inventory, net $ 18,648 $ 19,094 |
Schedule of Changes in the Company’s Inventory Reserve | Changes in the Company’s inventory reserve are as follows: (In thousands) Three Year Inventory reserves – beginning of period $ 17,599 $ 32,422 (Decrease) increase in inventory reserves (415 ) (14,823 ) Inventory reserves – end of period $ 17,184 $ 17,599 |
Debt (Tables)
Debt (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Debt [Abstract] | |
Schedule of Debt | The Company’s debt consisted of: (In thousands) March 31, December 31, Related party debt: Consolidated CP Acquisitions Note $ 17,683 $ — CP Acquisitions Junior Secured Note — 3,799 GIC Acquisition Note 1,000 645 Total related party debt 18,683 4,444 Less: current portion (1,000 ) (4,444 ) Related party debt, net of current $ 17,683 $ — Long-term debt: Exchange Note $ — $ 6,669 Convertible Note — 7,840 PPP Loan 517 518 Other notes payable (1) 226 367 Unamortized debt premium — 1,419 Total long-term debt 743 16,813 Less: current portion (696 ) (766 ) Long-term debt, net of current $ 47 $ 16,047 (1) Other notes payable relates to a one-year insurance premium that was financed over nine-months and incurred interest expense of approximately $7 thousand for the three months ended March 31, 2024. Other notes payable also includes the Navitas Loan with a balance of $5 thousand as of March 31, 2024. |
Schedule of Future Minimum Payments | As of March 31, 2024, future minimum payments on all debt positions were as follows: Years ending December 31 (In thousands), Remaining 2024 $ 2,487 2025 16,938 Total future payments $ 19,426 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Leases [Abstract] | |
Schedule of Operating and Financing Lease Activity | Additional information on the Company’s operating and financing lease activity was as follows: Three months ended (In thousands) 2024 2023 Operating lease cost $ 130 $ 236 Finance lease cost: Amortization of right-of-use assets — 45 Interest on lease liabilities — 6 Total lease cost $ 130 $ 287 |
Schedule of Weighted-Average Remaining Operating and Financing Lease Term | March 31, December 31, Weighted-average remaining lease term – operating leases 2.85 years 3.09 years Weighted-average remaining lease term – finance leases — — Weighted-average discount rate – operating leases 7.50 % 7.51 % Weighted-average discount rate – finance leases — % — % |
Schedule of Operating Assets and Liabilities | (In thousands) Balance Sheet March 31, December 31, Assets Right-of-use assets, net Right-of-use, net $ 1,651 $ 1,803 Total lease assets $ 1,651 $ 1,803 Liabilities Operating lease liabilities, current Operating lease liabilities, current $ 615 $ 599 Operating lease liabilities, non-current Operating lease liabilities, non-current 1,235 1,394 Total operating lease liabilities $ 1,850 $ 1,993 |
Schedule of Maturities of Operating Lease Liabilities | Maturities of operating lease liabilities as of March 31, 2024 are as follows: Years ending December 31 (In thousands), Operating Remaining 2024 548 2025 748 2026 560 2027 202 Total minimum lease payments 2,058 Less discount (208 ) Total lease liabilities $ 1,850 |
Stock-Based Compensation and _2
Stock-Based Compensation and Employee Benefit Plans (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Stock-Based Compensation and Employee Benefit Plans [Abstract] | |
Schedule of Options Vested and Exercisable | The following table summarizes information about options vested and exercisable at March 31, 2024: Options Vested and Exercisable Price ($) Number of Options Weighted-Average Weighted-Average Exercise Price $ 456.00 2,884 6.12 $ 456.00 $ 972.00 2,842 6.57 $ 972.00 $ 1,536.00 50 7.00 $ 1,536.00 $ 1,840.00 160 7.75 $ 1,840.00 $ 2,768.00 4,270 6.89 $ 2,768.00 Options Vested and Expected to Vest Price ($) Number of Options Weighted-Average Weighted-Average Exercise Price $ 456.00 2,884 6.12 $ 456.00 $ 972.00 2,856 6.57 $ 972.00 $ 1,536.00 50 7.00 $ 1,536.00 $ 1,840.00 250 7.75 $ 1,840.00 $ 2,768.00 4,270 6.89 $ 2,768.00 |
Schedule of Restricted Stock Unit Activity | The following table presents restricted stock unit activity under the 2022 Plan for the three months ended March 31, 2024: Number of Weighted- Unvested at December 31, 2023 2,136 230.80 Granted 201,938 0.76 Vested (201,955 ) 0.79 Forfeited (284 ) 82.20 Unvested at March 31, 2024 1,835 $ 251.22 |
Stock Warrants (Tables)
Stock Warrants (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Stock Warrants [Abstract] | |
Schedule of Warrant Activity | The following tables present all warrant activity of the Company for the three months ended March 31, 2024: Number of Weighted- Exercise Warrants outstanding at December 31, 2023 5,380,299 $ 10.83 Granted 4,030,921 0.03 Exercised (6,142,217 ) — Forfeited (3,081 ) — Warrants outstanding at March 31, 2024 3,265,922 $ 17.50 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Net Loss Per Share [Abstract] | |
Schedule of Basic and Diluted Net Loss Per Share | The components of basic and diluted net loss per share were as follows: Three months ended (In thousands, except share and per share data) 2024 (As restated) 2023 Numerator: Numerator for diluted EPS - net (loss) income available to common stockholders after assumed conversions $ 4,533 $ (10,327 ) Effect of dilutive securities: Interest expense on convertible notes $ 297 $ — Numerator for diluted EPS - net (loss) income available to common stockholders after assumed conversions $ 4,533 $ (10,327 ) Denominator: Denominator for basic EPS - weighted-average common stock outstanding 8,894,229 1,072,292 Effect of dilutive securities: Conversion of convertible notes 11,066,376 — Denominator for diluted EPS - adjusted weighted-average common stock outstanding and assumed conversions 19,960,605 1,072,292 Basic net loss (income) per share attributable to common stockholders $ 0.48 $ (9.63 ) Diluted net loss (income) per share attributable to common stockholders $ 0.23 $ (9.63 ) |
Schedule of Anti-Dilutive Shares | The Company excluded the following potential Common Stock equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to Common Stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three months ended 2024 2023 Shares subject to outstanding stock options 10,206 10,562 Shares subject to unvested restricted stock units 1,835 6,307 Shares subject to outstanding warrants 3,265,922 1,495,001 3,277,963 1,511,870 |
Related Parties (Tables)
Related Parties (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Related Parties [Abstract] | |
Schedule of Net Purchasing (Sales) Activity | The following table describes the net purchasing (sales) activity with entities identified as related parties to the Company: Three months ended (In thousands) 2024 2023 Bluezone $ — $ 4 Topline Performance Group — (1 ) NEIA — (43 ) Greenstone Holdings — (2 ) |
Schedule of Net Related Party (Payable) Receivable | The following table summarizes net related party (payable) receivable as of March 31, 2024 and December 31, 2023: (In thousands) March 31, December 31, Bluezone $ — $ (4 ) Valiant Americas, LLC — 1 |
Overview, Basis of Presentati_3
Overview, Basis of Presentation and Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||
Dec. 01, 2023 | Feb. 28, 2024 | Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | Oct. 04, 2022 | |||
Overview, Basis of Presentation and Significant Accounting Policies [Line Items] | ||||||||
Received amount | $ 17,170 | |||||||
Stockholders equity | $ 2,500 | |||||||
Common stock, par value (in Dollars per share) | $ 0.001 | [1] | $ 0.001 | [1] | $ 1 | |||
Accumulated deficit | $ (261,561) | $ (265,797) | ||||||
Cash equivalents, and marketable securities | 100 | |||||||
Current liabilities | 26,716 | 41,249 | ||||||
Net proceeds | $ 2,200 | |||||||
Reserve for warranty returns | $ 400 | $ 400 | ||||||
Agrify Valiant, LLC’s [Member] | ||||||||
Overview, Basis of Presentation and Significant Accounting Policies [Line Items] | ||||||||
Equity interest percentage | 60% | |||||||
Agrify Brands, LLC’s [Member] | ||||||||
Overview, Basis of Presentation and Significant Accounting Policies [Line Items] | ||||||||
Equity interest percentage | 75% | |||||||
Exchange Note [Member] | ||||||||
Overview, Basis of Presentation and Significant Accounting Policies [Line Items] | ||||||||
Current liabilities | $ 26,700 | |||||||
Customer Concentration Risk [Member] | Customer One [Member] | Revenue Benchmark [Member] | ||||||||
Overview, Basis of Presentation and Significant Accounting Policies [Line Items] | ||||||||
Concentration risk, percentage | 1% | 11% | ||||||
Customer Concentration Risk [Member] | Customer Two [Member] | Revenue Benchmark [Member] | ||||||||
Overview, Basis of Presentation and Significant Accounting Policies [Line Items] | ||||||||
Concentration risk, percentage | 47% | 84% | ||||||
[1]Periods presented have been adjusted to reflect the 1-for-20 reverse stock split on July 5, 2023. Additional information regarding the reverse stock splits may be found in Note 1 – Overview, Basis of Presentation, and Significant Accounting Policies, included in the notes to the consolidated financial statements |
Overview, Basis of Presentati_4
Overview, Basis of Presentation and Significant Accounting Policies (Details) - Schedule of Effect of The Errors on the Company’s Consolidated Balance Sheet $ in Thousands | Mar. 31, 2024 USD ($) |
Previously Reported [Member] | |
Condensed Balance Sheet Statements, Captions [Line Items] | |
Inventory | $ 18,862 |
Accounts payable | 12,428 |
Notes payable, current | 1,374 |
Notes payable, net of current | 3,464 |
Accumulated deficit | (265,835) |
Total stockholders’ deficit attributable to Agrify | (9,725) |
Revision of Prior Period, Adjustment [Member] | |
Condensed Balance Sheet Statements, Captions [Line Items] | |
Inventory | (214) |
Accounts payable | 350 |
Notes payable, current | (1,374) |
Notes payable, net of current | (3,464) |
Accumulated deficit | 4,274 |
Total stockholders’ deficit attributable to Agrify | 4,274 |
As Restated [Member] | |
Condensed Balance Sheet Statements, Captions [Line Items] | |
Inventory | 18,648 |
Accounts payable | 12,778 |
Notes payable, current | |
Notes payable, net of current | |
Accumulated deficit | (261,561) |
Total stockholders’ deficit attributable to Agrify | $ (5,451) |
Overview, Basis of Presentati_5
Overview, Basis of Presentation and Significant Accounting Policies (Details) - Schedule of Consolidated Statement of Operations $ / shares in Units, $ in Thousands | 3 Months Ended |
Mar. 31, 2024 USD ($) $ / shares | |
Previously Reported [Member] | |
Condensed Income Statements, Captions [Line Items] | |
Cost of goods sold | $ 1,869 |
Gross profit | 729 |
General and administrative | 2,952 |
Gain on settlement of contingent liabilities | |
Operating (loss) income | (780) |
Interest income (expense), net | (145) |
Net (loss) income | $ (38) |
Basic (in Dollars per share) | $ / shares | $ 0 |
Diluted (in Dollars per share) | $ / shares | $ 0 |
Revision of Prior Period, Adjustment [Member] | |
Condensed Income Statements, Captions [Line Items] | |
Cost of goods sold | $ 564 |
Gross profit | (564) |
General and administrative | 1,142 |
Gain on settlement of contingent liabilities | (5,935) |
Operating (loss) income | 4,229 |
Interest income (expense), net | 45 |
Net (loss) income | $ 4,274 |
Basic (in Dollars per share) | $ / shares | $ 0.48 |
Diluted (in Dollars per share) | $ / shares | $ 0.23 |
As Restated [Member] | |
Condensed Income Statements, Captions [Line Items] | |
Cost of goods sold | $ 2,433 |
Gross profit | 165 |
General and administrative | 4,094 |
Gain on settlement of contingent liabilities | (5,935) |
Operating (loss) income | 3,449 |
Interest income (expense), net | (100) |
Net (loss) income | $ 4,236 |
Basic (in Dollars per share) | $ / shares | $ 0.48 |
Diluted (in Dollars per share) | $ / shares | $ 0.23 |
Overview, Basis of Presentati_6
Overview, Basis of Presentation and Significant Accounting Policies (Details) - Schedule of Consolidated Statement of Cash Flows $ in Thousands | 3 Months Ended |
Mar. 31, 2024 USD ($) | |
Previously Reported [Member] | |
Cash flows from operating activities | |
Net loss | $ (38) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Gain on supply agreement | (1,142) |
Gain on revaluation of contingent liability | (564) |
Gain on settlement of contingent liabilities | |
Changes in operating assets and liabilities | |
Inventory | 1,211 |
Accounts payable | (2,361) |
Net cash used in operating activities | (2,987) |
Revision of Prior Period, Adjustment [Member] | |
Cash flows from operating activities | |
Net loss | 4,274 |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Gain on supply agreement | 1,142 |
Gain on revaluation of contingent liability | 564 |
Gain on settlement of contingent liabilities | (5,935) |
Changes in operating assets and liabilities | |
Inventory | (350) |
Accounts payable | 305 |
Net cash used in operating activities | |
As Restated [Member] | |
Cash flows from operating activities | |
Net loss | 4,236 |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Gain on supply agreement | |
Gain on revaluation of contingent liability | |
Gain on settlement of contingent liabilities | (5,935) |
Changes in operating assets and liabilities | |
Inventory | 861 |
Accounts payable | (2,056) |
Net cash used in operating activities | $ (2,987) |
Overview, Basis of Presentati_7
Overview, Basis of Presentation and Significant Accounting Policies (Details) - Schedule of Property and Equipment Estimated Useful Life | Mar. 31, 2024 |
Furniture and Fixtures [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 2 years |
Software Development [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 3 years |
Vehicles [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 5 years |
Research and Development of Laboratory Equipment [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 5 years |
Leasehold Improvements [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life description | Lower of estimated useful life or remaining lease term |
Minimum [Member] | Computer Equipment [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 2 years |
Minimum [Member] | Machinery and Equipment [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 3 years |
Minimum [Member] | Leased Equipment [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 5 years |
Minimum [Member] | Trade Show Assets [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 3 years |
Maximum [Member] | Computer Equipment [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 3 years |
Maximum [Member] | Machinery and Equipment [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 5 years |
Maximum [Member] | Leased Equipment [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 13 years |
Maximum [Member] | Trade Show Assets [Member] | |
Schedule of Property and Equipment Estimated Useful Life [Line Items] | |
Property and equipment estimated useful life | 5 years |
Revenue and Contract Liabilit_3
Revenue and Contract Liabilities (Details) - Schedule of Revenue Disaggregated by the Timing of Revenue Recognition - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 2,598 | $ 5,804 |
Transferred at Point in Time [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | 2,465 | 4,920 |
Transferred over Time [Member] | ||
Disaggregation of Revenue [Line Items] | ||
Total revenue | $ 133 | $ 884 |
Revenue and Contract Liabilit_4
Revenue and Contract Liabilities (Details) - Schedule of Current Deferred Revenue - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2024 | Dec. 31, 2023 | |
Schedule of Current Deferred Revenue [Abstract] | ||
Contract liabilities – beginning of period | $ 4,019 | $ 4,112 |
Additions | 1,160 | 4,905 |
Recognized | (1,395) | (4,998) |
Contract liabilities – end of period | $ 3,784 | $ 4,019 |
Supplemental Condensed Consol_3
Supplemental Condensed Consolidated Balance Sheet Information (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Supplemental Consolidated Balance Sheet Information [Abstract] | |||
Settlement agreement | $ 500,000 | ||
Recovery of credit losses | $ 400,000 | $ 400,000 | |
Proceeds property and equipment | 105,000 | ||
Sale property and equipment | 144,000 | ||
Gain of property and equipment | $ 444,000 |
Supplemental Condensed Consol_4
Supplemental Condensed Consolidated Balance Sheet Information (Details) - Schedule of Accounts Receivable - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Schedule of Accounts Receivable [Abstract] | ||
Accounts receivable, gross | $ 2,723 | $ 3,036 |
Less allowance for credit losses | (2,512) | (1,887) |
Accounts receivable, net | $ 211 | $ 1,149 |
Supplemental Condensed Consol_5
Supplemental Condensed Consolidated Balance Sheet Information (Details) - Schedule of Allowance for Credit Losses Accounts - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2024 | Dec. 31, 2023 | |
Schedule of Allowance for Credit Losses Accounts [Abstract] | ||
Allowance for credit losses - beginning of period | $ 1,887 | $ 4,605 |
Allowance for credit losses - end of period | 2,512 | 1,887 |
(Recovery of) allowance for credit losses | 642 | (1,426) |
Accounts receivable written-off | $ (17) | $ (1,292) |
Supplemental Condensed Consol_6
Supplemental Condensed Consolidated Balance Sheet Information (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Schedule of Prepaid Expenses and Other Current Assets [Abstract] | ||
Other receivables, other | $ 536 | $ 659 |
Prepaid insurance | 352 | 454 |
Prepaid expenses, other | 93 | 82 |
Prepaid software | 31 | 70 |
Prepaid materials | 16 | 13 |
Prepaid settlement asset | 2,054 | |
Total prepaid expenses and other current assets | $ 1,028 | $ 3,332 |
Supplemental Condensed Consol_7
Supplemental Condensed Consolidated Balance Sheet Information (Details) - Schedule of Property and Equipment, Net - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | $ 7,685 | $ 7,685 |
Accumulated depreciation | (3,300) | (2,894) |
Construction in progress | 2,943 | 2,943 |
Total property and equipment, net | 7,328 | 7,734 |
Leased equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | 4,465 | 4,465 |
Leasehold improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | 702 | 702 |
Machinery and equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | 904 | 904 |
Software [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | 606 | 606 |
Computer and office equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | 588 | 588 |
Research and development laboratory equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | 183 | 183 |
Furniture and fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | 116 | 116 |
Trade show assets [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | 78 | 78 |
Vehicles [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment, gross | $ 43 | $ 43 |
Supplemental Condensed Consol_8
Supplemental Condensed Consolidated Balance Sheet Information (Details) - Schedule of Accrued Expenses and Other Current Liabilities - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 | |
Schedule of Accrued Expenses and Other Current Liabilities [Abstract] | |||
Sales tax payable | [1] | $ 5,320 | $ 5,338 |
Accrued construction costs | 1,312 | 1,412 | |
Accrued professional fees | 423 | 457 | |
Accrued warranty expenses | 415 | 420 | |
Compensation related fees | 313 | 474 | |
Accrued consulting fees | 45 | 43 | |
Accrued interest expense | 12 | 321 | |
Accrued inventory purchases | 3 | 10 | |
Accrued acquisition liabilities | 2,180 | ||
Total accrued expenses and other current liabilities | $ 7,843 | $ 10,655 | |
[1] Sales tax payable primarily represents identified sales and use tax liabilities arising from our acquisition of Precision and Cascade. These amounts are included as part of our initial purchase price allocations and are the subject matter of an indemnification claim under the Precision and Cascade acquisition agreement. |
Fair Value Measures (Details)
Fair Value Measures (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Fair Value Measures [Line Items] | ||
Money market funds | $ 4 | $ 4 |
Fair Value Measures (Details) -
Fair Value Measures (Details) - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Assets: | ||
Total assets | $ 4 | $ 4 |
Liabilities: | ||
Total liabilities | 417 | 1,290 |
Level 1 [Member] | ||
Assets: | ||
Total assets | 4 | 4 |
Liabilities: | ||
Total liabilities | ||
Level 2 [Member] | ||
Assets: | ||
Total assets | ||
Liabilities: | ||
Total liabilities | ||
Level 3 [Member] | ||
Assets: | ||
Total assets | ||
Liabilities: | ||
Total liabilities | 417 | 1,290 |
Money market funds [Member] | ||
Assets: | ||
Total assets | 4 | 4 |
Money market funds [Member] | Level 1 [Member] | ||
Assets: | ||
Total assets | 4 | 4 |
Money market funds [Member] | Level 2 [Member] | ||
Assets: | ||
Total assets | ||
Money market funds [Member] | Level 3 [Member] | ||
Assets: | ||
Total assets | ||
Warrant liabilities - January 2022 warrants [Member] | ||
Liabilities: | ||
Total liabilities | 1 | |
Warrant liabilities - January 2022 warrants [Member] | Level 1 [Member] | ||
Liabilities: | ||
Total liabilities | ||
Warrant liabilities - January 2022 warrants [Member] | Level 2 [Member] | ||
Liabilities: | ||
Total liabilities | ||
Warrant liabilities - January 2022 warrants [Member] | Level 3 [Member] | ||
Liabilities: | ||
Total liabilities | 1 | |
Warrant liabilities - March 2022 warrants [Member] | ||
Liabilities: | ||
Total liabilities | 1 | 7 |
Warrant liabilities - March 2022 warrants [Member] | Level 1 [Member] | ||
Liabilities: | ||
Total liabilities | ||
Warrant liabilities - March 2022 warrants [Member] | Level 2 [Member] | ||
Liabilities: | ||
Total liabilities | ||
Warrant liabilities - March 2022 warrants [Member] | Level 3 [Member] | ||
Liabilities: | ||
Total liabilities | 1 | 7 |
Warrant liabilities - August 2022 warrants [Member] | ||
Liabilities: | ||
Total liabilities | 3 | 18 |
Warrant liabilities - August 2022 warrants [Member] | Level 1 [Member] | ||
Liabilities: | ||
Total liabilities | ||
Warrant liabilities - August 2022 warrants [Member] | Level 2 [Member] | ||
Liabilities: | ||
Total liabilities | ||
Warrant liabilities - August 2022 warrants [Member] | Level 3 [Member] | ||
Liabilities: | ||
Total liabilities | 3 | 18 |
Warrant liabilities - December 2022 warrants [Member] | ||
Liabilities: | ||
Total liabilities | 413 | 1,264 |
Warrant liabilities - December 2022 warrants [Member] | Level 1 [Member] | ||
Liabilities: | ||
Total liabilities | ||
Warrant liabilities - December 2022 warrants [Member] | Level 2 [Member] | ||
Liabilities: | ||
Total liabilities | ||
Warrant liabilities - December 2022 warrants [Member] | Level 3 [Member] | ||
Liabilities: | ||
Total liabilities | $ 413 | $ 1,264 |
Fair Value Measures (Details)_2
Fair Value Measures (Details) - Schedule of Company’s Assumptions Used in the Valuations - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2024 | Dec. 31, 2023 | |
January 2022 Warrants [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Stock price | $ 0.37 | $ 1.26 |
Exercise price | $ 1,496 | $ 1,496 |
Expected term (in Years) | 3 years 3 months 25 days | 3 years 6 months 25 days |
Volatility | 136% | 138% |
Discount rate - treasury yield | 4.37% | 3.96% |
March 2022 Warrants [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Stock price | $ 0.37 | $ 1.26 |
Exercise price | $ 430 | $ 430 |
Expected term (in Years) | 3 years 10 months 17 days | 4 years 1 month 17 days |
Volatility | 138% | 136% |
Discount rate - treasury yield | 4.32% | 3.91% |
August 2022 Warrants [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Stock price | $ 0.37 | $ 1.26 |
Exercise price | $ 246 | $ 246 |
Expected term (in Years) | 3 years 10 months 17 days | 4 years 1 month 17 days |
Volatility | 138% | 136% |
Discount rate - treasury yield | 4.32% | 3.91% |
December 2022 Warrants [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Stock price | $ 0.37 | $ 1.26 |
Exercise price | $ 0.38 | $ 3.45 |
Expected term (in Years) | 3 years 10 months 17 days | 4 years 1 month 17 days |
Volatility | 138% | 136% |
Discount rate - treasury yield | 4.32% | 3.91% |
Fair Value Measures (Details)_3
Fair Value Measures (Details) - Schedule of Changes in the Fair Value of the Level 3 Warrant Liabilities - January 2022 Warrants [Member] - Level 3 [Member] - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2024 | Dec. 31, 2023 | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||
Warrant liabilities – beginning of period | $ 1,290 | $ 5,985 |
Warrant liabilities –end of period | 417 | 1,290 |
Change in estimated fair value | $ (873) | $ (4,695) |
Loans Receivable (Details)
Loans Receivable (Details) - USD ($) | 3 Months Ended | ||
Oct. 31, 2023 | Mar. 31, 2024 | Dec. 31, 2023 | |
Loans Receivable [Line Items] | |||
Business plans period | 10 years | ||
Interest rate | 16% | ||
Established reserve | $ 14,700,000 | ||
Allowance for credit losses percentage | 50% | ||
Loan receivable | $ 4,500,000 | ||
Additional allowance loan payable | $ 250,000 | ||
Allowance loan | 4,500,000 | ||
TTK loan[Member] | |||
Loans Receivable [Line Items] | |||
Current balance of loan | $ 692 | ||
Bud & Mary’s [Member] | |||
Loans Receivable [Line Items] | |||
Allowance for credit losses | $ 330,000,000 |
Loans Receivable (Details) - Sc
Loans Receivable (Details) - Schedule of Breakdown of Loans Receivable by Customer - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Customer 139 [Member] | ||
Schedule of Breakdown of Loans Receivable by Customer [Line Items] | ||
Loan receivable | $ 14,361 | $ 14,691 |
Customer 125 [Member] | ||
Schedule of Breakdown of Loans Receivable by Customer [Line Items] | ||
Loan receivable | 9,297 | 9,297 |
Customer 24096 [Member] | ||
Schedule of Breakdown of Loans Receivable by Customer [Line Items] | ||
Loan receivable | 6,810 | 6,810 |
Allowance for credit losses [Member] | ||
Schedule of Breakdown of Loans Receivable by Customer [Line Items] | ||
Allowance for credit losses | (18,885) | (19,215) |
Total loan receivable, net of allowance for credit losses | 11,583 | 11,583 |
Other – Non-TTK Solution [Member] | ||
Schedule of Breakdown of Loans Receivable by Customer [Line Items] | ||
Less: current portion | (692) | |
Total loan receivable, net of current | $ 10,891 | $ 11,583 |
Inventory (Details) - Schedule
Inventory (Details) - Schedule of Inventory - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Schedule of Inventory [Abstract] | ||
Raw materials | $ 22,392 | $ 23,449 |
Prepaid inventory | 816 | 924 |
Finished goods | 7,848 | 7,438 |
Inventory for resale | 4,776 | 4,882 |
Inventory, gross | 35,832 | 36,693 |
Inventory reserves | (17,184) | (17,599) |
Total inventory, net | $ 18,648 | $ 19,094 |
Inventory (Details) - Schedul_2
Inventory (Details) - Schedule of Changes in the Company’s Inventory Reserve - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2024 | Dec. 31, 2023 | |
Schedule of Changes in the Company’s Inventory Reserve [Abstract] | ||
Inventory reserves – beginning of period | $ 17,599 | $ 32,422 |
(Decrease) increase in inventory reserves | (415) | (14,823) |
Inventory reserves – end of period | $ 17,184 | $ 17,599 |
Debt (Details)
Debt (Details) - USD ($) | 3 Months Ended | ||||||||||||
Dec. 31, 2025 | Dec. 31, 2024 | Aug. 19, 2023 | Aug. 06, 2023 | Jul. 31, 2023 | Jul. 12, 2023 | May 01, 2023 | Apr. 26, 2023 | Mar. 08, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | Nov. 30, 2023 | |
Debt [Line Items] | |||||||||||||
Incurred interest expense | $ 7,000 | ||||||||||||
Amortization payments rate | 9% | 9% | |||||||||||
Interest on rate per year percentage | 30% | 20% | |||||||||||
Principal balance | $ 10,000,000 | ||||||||||||
Original principal amount | 102.50% | ||||||||||||
Outstanding principal amount percentage | 115% | ||||||||||||
Convertible Note | 30% | ||||||||||||
Outstanding principal amount | $ 2,000,000 | $ 1,600,000 | |||||||||||
Outstanding principal | 4.99% | ||||||||||||
Shares of Common Stock (in Shares) | 69,568 | ||||||||||||
Junior Secured Note | $ 3,000,000 | ||||||||||||
Interest rate per annum | 10% | ||||||||||||
Outstanding principal | $ 18,717,973 | ||||||||||||
Loan interest rate | 10% | ||||||||||||
Redeem portion amount | $ 5,000,000 | ||||||||||||
Aggregate excess in common stock | 49.99% | ||||||||||||
Outstanding principal amount | $ 3,900,000 | ||||||||||||
Aggregate shares of common stock (in Shares) | 2,671,633 | ||||||||||||
Fair value | $ 1,700,000 | ||||||||||||
Excess carrying value | 675,000 | ||||||||||||
Debt issuance | $ 24,000 | ||||||||||||
Issuance remaining | $ 200,000 | ||||||||||||
Interest rate | 10% | ||||||||||||
Letter Agreement [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Outstanding principal | 4.99% | ||||||||||||
Convertible Notes [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Interest on rate per year percentage | 20% | ||||||||||||
Original principal amount | 102.50% | ||||||||||||
Gross proceeds | $ 8,000,000 | ||||||||||||
Fundamental change percentage | 102.50% | ||||||||||||
Interest rate per year | 15% | ||||||||||||
Conversion price per share (in Dollars per share) | $ 7.64 | ||||||||||||
Aggregate excess | 4.99% | ||||||||||||
Convertible Notes interest expense | $ 116 | ||||||||||||
Outstanding principal amount | $ 1,000,000 | ||||||||||||
Conversion Rate [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Outstanding principal amount percentage | 115% | ||||||||||||
Letter Agreement [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Gain on debt | $ 12,000 | ||||||||||||
Conversion Price [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Conversion price per share (in Dollars per share) | $ 1.46 | ||||||||||||
GIC Acquisition, LLC [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Debt issuance | $ 300,000 | ||||||||||||
Related Party [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Other notes payable | $ 17,683,000 | ||||||||||||
Interest expense | 24,000 | ||||||||||||
Borrowings | 1,000 | ||||||||||||
Chief Executive Officer [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Total proceeds amount | $ 500,000 | ||||||||||||
Navitas Loan [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Other notes payable | $ 5,000 | ||||||||||||
Note Conversion [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Convertible note shares of common stock (in Shares) | 445,196 | 153,617 | |||||||||||
Ownership Limitation [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Ownership percentage | 9.99% | ||||||||||||
Common Stock [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Remaining shares issued (in Shares) | 375,629 | ||||||||||||
Forecast [Member] | |||||||||||||
Debt [Line Items] | |||||||||||||
Loaned principal amount | $ 4,000,000 |
Debt (Details) - Schedule of De
Debt (Details) - Schedule of Debt - Debt [Member] - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 | |
Related party debt: | |||
Consolidated CP Acquisitions Note | $ 17,683 | ||
CP Acquisitions Junior Secured Note | 3,799 | ||
GIC Acquisition Note | 1,000 | 645 | |
Total related party debt | 18,683 | 4,444 | |
Long-term debt: | |||
Exchange Note | 6,669 | ||
Convertible Note | 7,840 | ||
PPP Loan | 517 | 518 | |
Other notes payable | [1] | 226 | 367 |
Unamortized debt premium | 1,419 | ||
Total long-term debt | 743 | 16,813 | |
Less: current portion | (696) | (766) | |
Long-term debt, net of current | 47 | 16,047 | |
Related Party [Member] | |||
Related party debt: | |||
Less: current portion | (1,000) | (4,444) | |
Related party debt, net of current | $ 17,683 | ||
[1] Other notes payable relates to a one-year insurance premium that was financed over nine-months and incurred interest expense of approximately $7 thousand for the three months ended March 31, 2024. Other notes payable also includes the Navitas Loan with a balance of $5 thousand as of March 31, 2024. |
Debt (Details) - Schedule of Fu
Debt (Details) - Schedule of Future Minimum Payments $ in Thousands | Mar. 31, 2024 USD ($) |
Schedule of Future Minimum Payments [Abstract] | |
Remaining 2024 | $ 2,487 |
2025 | 16,938 |
Total future payments | $ 19,426 |
Leases (Details)
Leases (Details) | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating Leased Assets [Line Items] | ||
Weighted-average discount rate | 7.50% | 7.51% |
Leases (Details) - Schedule of
Leases (Details) - Schedule of Operating and Financing Lease Activity - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Schedule of Operating and Financing Lease Activity [Abstract] | ||
Operating lease cost | $ 130 | $ 236 |
Finance lease cost: | ||
Amortization of right-of-use assets | 45 | |
Interest on lease liabilities | 6 | |
Total lease cost | $ 130 | $ 287 |
Leases (Details) - Schedule o_2
Leases (Details) - Schedule of Weighted-Average Remaining Operating and Financing Lease Term | Mar. 31, 2024 | Dec. 31, 2023 |
Schedule of Weighted Average Remaining Operating and Financing Lease Term [Abstract] | ||
Weighted-average remaining lease term – operating leases | 2 years 10 months 6 days | 3 years 1 month 2 days |
Weighted-average remaining lease term – finance leases | ||
Weighted-average discount rate – operating leases | 7.50% | 7.51% |
Weighted-average discount rate – finance leases |
Leases (Details) - Schedule o_3
Leases (Details) - Schedule of Operating Assets and Liabilities - Lease Liability [Member] - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Dec. 31, 2023 | |
Assets | ||
Balance Sheet Location, Right-of-use assets, net | Right-of-use, net | |
Right-of-use assets, net | $ 1,651 | $ 1,803 |
Total lease assets | $ 1,651 | 1,803 |
Liabilities | ||
Balance Sheet Location, Operating lease liabilities, current | Operating lease liabilities, current | |
Operating lease liabilities, current | $ 615 | 599 |
Balance Sheet Location, Operating lease liabilities, non-current | Operating lease liabilities, non-current | |
Operating lease liabilities, non-current | $ 1,235 | 1,394 |
Total operating lease liabilities | $ 1,850 | $ 1,993 |
Leases (Details) - Schedule o_4
Leases (Details) - Schedule of Maturities of Operating Lease Liabilities - Operating Lease [Member] $ in Thousands | Mar. 31, 2024 USD ($) |
Schedule of Maturities of Operating Lease Liabilities [Line Items] | |
Remaining 2024 | $ 548 |
2025 | 748 |
2026 | 560 |
2027 | 202 |
Total minimum lease payments | 2,058 |
Less discount | (208) |
Total lease liabilities | $ 1,850 |
Stockholders_ Deficit (Details)
Stockholders’ Deficit (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | ||
Jan. 25, 2022 | Mar. 31, 2024 | May 01, 2023 | |
Stockholders’ Equity [Line Items] | |||
warrants issued | 69,568 | ||
Investor warrants was estimated | $ 31 | ||
Alexander Capital [Member] | |||
Stockholders’ Equity [Line Items] | |||
warrants issued | 67,237 | ||
Exercise price percentage | 100% | ||
Share price | $ 0.52 | ||
Exercise price per share | $ 0.38 | ||
Warrants term | 5 years | ||
Volatility Percentage | 128% | ||
Risk-free rate percentage | 4.32% | ||
Dividend rate | 0% | ||
Private Placement [Member] | |||
Stockholders’ Equity [Line Items] | |||
Warrant per shares | $ 0.001 | ||
Private Placement [Member] | Common Stock [Member] | |||
Stockholders’ Equity [Line Items] | |||
Additional shares of common stock | 2,760,000 | ||
Purchase of aggregate shares | 3,963,684 | ||
Purchase price of stock | $ 0.38 |
Stock-Based Compensation and _3
Stock-Based Compensation and Employee Benefit Plans (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | ||||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Apr. 29, 2022 | |
Stock-Based Compensation and Employee Benefit Plans [Line Items] | |||||
Stock compensation expense (in Dollars) | $ 0.5 | $ 0.9 | |||
Options outstanding | 10,310 | ||||
Weighted average exercise price (in Dollars per share) | $ 1,594.66 | $ 1,595.92 | |||
Share options vested and exercisable | 10,206 | ||||
Unrecognized compensation expense (in Dollars) | $ 1.5 | ||||
Stock Options [Member] | |||||
Stock-Based Compensation and Employee Benefit Plans [Line Items] | |||||
Weighted average exercise price (in Dollars per share) | $ 1,595.92 | ||||
Share options vested and exercisable | 10,310 | ||||
Restricted Stock Units (RSUs) [Member] | |||||
Stock-Based Compensation and Employee Benefit Plans [Line Items] | |||||
Unrecognized compensation expense (in Dollars) | $ 139 | ||||
Weighted average period | 1 year 1 month 13 days | ||||
Common Stock [Member] | |||||
Stock-Based Compensation and Employee Benefit Plans [Line Items] | |||||
Shares outstanding | 13,275,702 | 1,364,263 | 1,701,243 | 1,038,298 | |
Common Stock [Member] | 2022 Plan [Member] | |||||
Stock-Based Compensation and Employee Benefit Plans [Line Items] | |||||
Shares available for grant | 57,719 | ||||
Shares outstanding | 250,000 | ||||
2022 Plan [Member] | |||||
Stock-Based Compensation and Employee Benefit Plans [Line Items] | |||||
Shares available for grant | 26,483 |
Stock-Based Compensation and _4
Stock-Based Compensation and Employee Benefit Plans (Details) - Schedule of Options Vested and Exercisable | 3 Months Ended |
Mar. 31, 2024 $ / shares shares | |
456.00 [Member] | Options Vested and Exercisable [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 2,884 |
Weighted-Average Remaining Contractual Life (Years) | 6 years 1 month 13 days |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 456 |
456.00 [Member] | Options Vested and Expected to Vest [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 2,884 |
Weighted-Average Remaining Contractual Life (Years) | 6 years 1 month 13 days |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 456 |
972.00 [Member] | Options Vested and Exercisable [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 2,842 |
Weighted-Average Remaining Contractual Life (Years) | 6 years 6 months 25 days |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 972 |
972.00 [Member] | Options Vested and Expected to Vest [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 2,856 |
Weighted-Average Remaining Contractual Life (Years) | 6 years 6 months 25 days |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 972 |
1,536.00 [Member] | Options Vested and Exercisable [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 50 |
Weighted-Average Remaining Contractual Life (Years) | 7 years |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 1,536 |
1,536.00 [Member] | Options Vested and Expected to Vest [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 50 |
Weighted-Average Remaining Contractual Life (Years) | 7 years |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 1,536 |
1,840.00 [Member] | Options Vested and Exercisable [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 160 |
Weighted-Average Remaining Contractual Life (Years) | 7 years 9 months |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 1,840 |
1,840.00 [Member] | Options Vested and Expected to Vest [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 250 |
Weighted-Average Remaining Contractual Life (Years) | 7 years 9 months |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 1,840 |
2,768.00 [Member] | Options Vested and Exercisable [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 4,270 |
Weighted-Average Remaining Contractual Life (Years) | 6 years 10 months 20 days |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 2,768 |
2,768.00 [Member] | Options Vested and Expected to Vest [Member] | |
Schedule of Options Vested and Exercisable [Line Items] | |
Number of Options | shares | 4,270 |
Weighted-Average Remaining Contractual Life (Years) | 6 years 10 months 20 days |
Weighted-Average Exercise Price (in Dollars per share) | $ / shares | $ 2,768 |
Stock-Based Compensation and _5
Stock-Based Compensation and Employee Benefit Plans (Details) - Schedule of Restricted Stock Unit Activity - Restricted Stock Units (RSUs) [Member] | 3 Months Ended |
Mar. 31, 2024 $ / shares shares | |
Schedule of Restricted Stock Unit Activity [Line Items] | |
Number of Shares, Unvested balance ending | shares | 2,136 |
Weighted- Average Grant Date Fair Value,Unvested balance ending | $ / shares | $ 230.8 |
Number of Shares, Granted | shares | 201,938 |
Weighted Average Grant Date Fair Value, Granted | $ / shares | $ 0.76 |
Number of Shares, Vested | shares | (201,955) |
Weighted Average Grant Date Fair Value, Vested | $ / shares | $ 0.79 |
Number of Shares, Forfeited | shares | (284) |
Weighted Average Grant Date Fair Value, Forfeited | $ / shares | $ 82.2 |
Number of Shares, Unvested balance ending | shares | 1,835 |
Weighted- Average Grant Date Fair Value,Unvested balance ending | $ / shares | $ 251.22 |
Stock Warrants (Details)
Stock Warrants (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2024 USD ($) | |
Stock Warrants [Member] | |
Stock Warrants [Line Items] | |
Exercise of warrants | $ 3 |
Stock Warrants (Details) - Sche
Stock Warrants (Details) - Schedule of Warrant Activity | 3 Months Ended |
Mar. 31, 2024 $ / shares shares | |
Warrant [Member] | |
Schedule of Warrant Activity [Line Items] | |
Number of Options, Options outstanding beginning | shares | 5,380,299 |
Number of Warrants Granted | shares | 4,030,921 |
Number of Warrants, Exercised | shares | (6,142,217) |
Number of Warrants , Forfeited | shares | (3,081) |
Number of Warrants, Options outstanding ending | shares | 3,265,922 |
Weighted Average Exercise Price [Member] | |
Schedule of Warrant Activity [Line Items] | |
Weighted- Average Exercise Price, outstanding beginning | $ / shares | $ 10.83 |
Weighted- Average Exercise Granted | $ / shares | 0.03 |
Weighted- Average Exercise Price, Exercised | $ / shares | |
Weighted- Average Exercise Price, Forfeited | $ / shares | |
Weighted- Average Exercise Price, outstanding ending | $ / shares | $ 17.5 |
Income Taxes (Details)
Income Taxes (Details) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2024 | Dec. 31, 2023 | |
Income Taxes [Line Items] | ||
Effective income tax rate | 0% | 0% |
Net Loss Per Share (Details)
Net Loss Per Share (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2024 USD ($) shares | |
Net Loss Per Share (Details) [Line Items] | |
Convertible notes outstanding principal balance (in Dollars) | $ | $ 14.8 |
Convertible shares | 2,671,633 |
Convertible Notes [Member] | |
Net Loss Per Share (Details) [Line Items] | |
Conversion shares | 10,332,411 |
Common Stock [Member] | |
Net Loss Per Share (Details) [Line Items] | |
Convertible shares | 2,671,633 |
Conversion shares | 2,671,633 |
Common Stock [Member] | Convertible Notes [Member] | |
Net Loss Per Share (Details) [Line Items] | |
Convertible shares | 10,332,411 |
Net Loss Per Share (Details) -
Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | ||
Numerator: | |||
Numerator for diluted EPS - net (loss) income available to common stockholders after assumed conversions | $ 4,533 | $ (10,327) | |
Effect of dilutive securities: | |||
Interest expense on convertible notes | 297 | ||
Numerator for diluted EPS - net (loss) income available to common stockholders after assumed conversions | $ 4,533 | $ (10,327) | |
Denominator: | |||
Denominator for basic EPS - weighted-average common stock outstanding | 8,894,229 | 1,072,292 | |
Effect of dilutive securities: | |||
Conversion of convertible notes | 11,066,376 | ||
Denominator for diluted EPS - adjusted weighted-average common stock outstanding and assumed conversions | 19,960,605 | 1,072,292 | |
Basic net loss (income) per share attributable to common stockholders | [1] | $ 0.48 | $ (9.63) |
Diluted net loss (income) per share attributable to common stockholders | [1] | $ 0.23 | $ (9.63) |
[1]Periods presented have been adjusted to reflect the 1-for-20 reverse stock split on July 5, 2023. Additional information regarding reverse stock splits may be found in Note 1 – Overview, Basis of Presentation, and Significant Accounting Policies, included elsewhere in the notes to the consolidated financial statements. |
Net Loss Per Share (Details) _2
Net Loss Per Share (Details) - Schedule of Anti-Dilutive Shares - shares | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Schedule of Anti-Dilutive Shares [Line Items] | ||
Anti-dilutive effect shares | 3,277,963 | 1,511,870 |
Shares subject to outstanding stock options [Member] | ||
Schedule of Anti-Dilutive Shares [Line Items] | ||
Anti-dilutive effect shares | 10,206 | 10,562 |
Shares subject to unvested restricted stock units [Member] | ||
Schedule of Anti-Dilutive Shares [Line Items] | ||
Anti-dilutive effect shares | 1,835 | 6,307 |
Shares subject to outstanding warrants [Member] | ||
Schedule of Anti-Dilutive Shares [Line Items] | ||
Anti-dilutive effect shares | 3,265,922 | 1,495,001 |
Commitments and Contingencies (
Commitments and Contingencies (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||
Apr. 25, 2024 | Feb. 22, 2023 | Jan. 31, 2024 | Oct. 31, 2023 | Sep. 30, 2023 | Feb. 28, 2022 | Dec. 31, 2021 | Feb. 28, 2021 | Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | Feb. 29, 2024 | Dec. 31, 2022 | Oct. 11, 2022 | Sep. 30, 2022 | Sep. 15, 2022 | |
Commitments and Contingencies [Line Items] | ||||||||||||||||
Reserve outstanding | $ 14,700,000 | |||||||||||||||
Contingent loss | $ 14,700,000 | |||||||||||||||
Due to nonpayment | $ 6,300,000 | |||||||||||||||
Accounts payable | 6,300,000 | |||||||||||||||
Claimed amount | 1,498,000 | |||||||||||||||
Purchase order mack amount | $ 26,500,000 | $ 5,200,000 | ||||||||||||||
Warrant to purchase (in Shares) | 750,000 | |||||||||||||||
Contingent liability | $ 5,900,000 | |||||||||||||||
Damages fees | $ 565,210 | |||||||||||||||
Litigation fees | $ 1,400,000 | |||||||||||||||
Award amount | 1,500,000 | |||||||||||||||
Settled legal customer recognition of a gain | $ 900,000 | 5,935,000 | ||||||||||||||
Paid amount | $ 300,000 | |||||||||||||||
Paid in equal monthly installments | $ 600,000 | |||||||||||||||
Receivable balance | 900,000 | |||||||||||||||
Outstanding receivable | 2,500,000 | |||||||||||||||
Storage fee | $ 25,000 | |||||||||||||||
Vertical Farming Units [Member] | ||||||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||||||
Inventory purchased | $ 8,400,000 | $ 9,400,000 | ||||||||||||||
Bowdoin Construction Corp. Litigation [Member] | ||||||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||||||
Claimed amount | $ 6,300,000 | |||||||||||||||
Mack Molding Co [Member] | ||||||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||||||
Purchase order mack amount | $ 26,500,000 | |||||||||||||||
Cash payments | $ 250,000 | |||||||||||||||
Payments to mack | 25 | |||||||||||||||
Purchase price | 14,000 | |||||||||||||||
Modification Agreement [Member] | Mack Molding Co [Member] | ||||||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||||||
Cash payments | $ 500,000 | |||||||||||||||
Subsequent Event [Member] | ||||||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||||||
Demanding value | $ 288,000 | |||||||||||||||
Minimum [Member] | ||||||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||||||
Aggregate net loss | 150,000 | |||||||||||||||
Maximum [Member] | ||||||||||||||||
Commitments and Contingencies [Line Items] | ||||||||||||||||
Aggregate net loss | $ 300,000 |
Related Parties (Details) - Sch
Related Parties (Details) - Schedule of Net Purchasing (Sales) Activity - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Bluezone [Member] | ||
Schedule of Net Purchasing (Sales) Activity [Line Items] | ||
Net purchase | $ 4 | |
Topline Performance Group [Member] | ||
Schedule of Net Purchasing (Sales) Activity [Line Items] | ||
Net purchase | (1) | |
NEIA [Member] | ||
Schedule of Net Purchasing (Sales) Activity [Line Items] | ||
Net purchase | (43) | |
Valiant Americas, LLC [Member] | ||
Schedule of Net Purchasing (Sales) Activity [Line Items] | ||
Net purchase | $ (2) |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ in Thousands | Aug. 07, 2024 | Jul. 24, 2024 | Apr. 30, 2024 |
Subsequent Event [Member] | Prefunded Warrants [Member] | |||
Subsequent Event [Line Items] | |||
Purchase of shares | 953,684 | ||
Subsequent Event [Member] | Warrant [Member] | |||
Subsequent Event [Line Items] | |||
Purchase of shares | 953,684 | ||
Forecast [Member] | CP Acquisitions, LLC [Member] | |||
Subsequent Event [Line Items] | |||
Cash contributions | $ 175 | $ 350 |